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i 
 
Summary 
 
This work examined the DNA-recognition and synapsis capabilities of Sin and Tn3 
resolvases, by alteration of regions of the protein to determine their significance for 
resolvase function. The importance of the E-helix (an -helical structure in the centre 
of the resolvase, connecting the catalytic domain and DNA-binding domain of the 
protein) of Sin recombinase, for DNA recognition at the centre of res site I, and for 
the formation of a synaptic tetramer was investigated. It was observed that swapping 
of the E-helix ‘arm’ region from Sin residues to the equivalent residues from Tn3 
resolvase abolished formation of the synapse. Truncated variants of Sin with the 
catalytic domain removed, termed ‘tadpoles’, were compared with a full-length 
activated mutant of Sin (Q115R) to determine the importance of the E-helices in 
formation of the synapse. From the ‘tadpole’ constructs, it was determined that the 
E-helix region between residues 109 and 124 is required for the formation of 
synaptic complexes, as deletion of this region was observed to abolish formation of 
the complex in vitro. Structure-guided single-residue mutations in this region of the 
E-helix further demonstrated that residues L112, I116 and M119, which are located 
on the flat hydrophobic interface between the E-helices of the Sin subunits in the 
synaptic tetramer complex, have a key role in the formation of this complex. Mutation 
of any of these residues to an alanine, both in the truncated Sin variants with a wild-
type background and in the full-length activated mutant Q115R blocks formation of 
this complex.  The truncated versions of Sin support the hypothesis that a bundle of 
four E–helices comprises a basic synapsis-competent module. In a related project, 
transcription activator-like effector recombinases (TALERs), chimeric constructs 
were constructed with the catalytic domain of an activated variant of Tn3 resolvase 
(NM) fused to the DNA binding domain of a TALE protein, TALERs with different N-
terminal TALE truncations were constructed. It was demonstrated that the TALER 
constructs were successfully targeted to designed cognate ‘T-sites’, utilising the 
DNA-binding specificity of the TALE domain. It was also demonstrated that some of 
the TALERs constructed are able to catalyse cleavage at T-sites in vitro.     
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g Grams  m Milli (10-3) 
h Hours   Micro (10
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min Minutes  n Nano (10-9) 
0C Degrees Celsius  p Pico (10-12) 
M Molar    
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Chapter 1: Introduction  
 
 
1.1 Recombination in Nature 
 
Recombination is the process by which two molecules of DNA (or RNA) are 
broken and re- joined. Recombination can occur between molecules of DNA 
which are similar, as in homologous recombination (HR), or different as seen 
in non-homologous end joining (NHEJ). Bacteria and eukaryotic organisms 
use recombination as a DNA repair mechanism, for resolution of plasmid 
multimers and for co-integrate resolution. In eukaryotic organisms, 
recombination also has a role in meiosis, where chromosomal crossover 
events lead to increased genetic diversity. 
 
 
1.1.i Homologous recombination 
 
Homologous recombination involves the exchange of DNA between two 
regions which share the same or very similar sequence, and requires 
complex protein machinery. Homologous recombination involves the 
formation of Holliday junction intermediates, branch migration of the junction 
and resolution to form recombinant molecules (Holliday 1964; Ariyoshi et al. 
2000). This type of recombination is important for maintaining the integrity of 
the genome, creating new diversity, rescue of stalled replication forks, 
directing gene expression, controlling the segregation of chromosomes and 
telomere maintenance (Camerini-Otero and Hsieh; 1995, San Fillipo et al. 
2008).  
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1.1.ii Site-specific recombination  
 
Site-specific recombination involves the reciprocal exchange of DNA strands 
with limited sequence homology by the breakage, re-arrangement and joining 
of molecules of DNA. The basic requirements for carrying out a site-specific 
recombination reaction are two DNA partners containing short recognition 
sequences (sites) usually between 30 and 200 base pairs in length, and a 
specialised recombinase protein. Recombinase recognises and binds to its 
cognate sites, then carries out strand cleavage, exchange and re-ligation of 
the DNA to a new partner. This reaction stores energy by the formation of a 
covalent protein-DNA intermediate at strand cleavage, and thus does not 
require a high energy co-factor such as ATP (Grindley 1994; Grindley et al. 
2006).     
 
Site-specific recombinases have the potential to undergo three reaction types; 
Excision, inversion and integration (Figure 1.1); which of these reactions is 
carried out is determined and tightly regulated by topological selectivity and 
site orientation (Grindley et al. 2006). Recombination between two linear DNA 
molecules yields two linear recombinant products.  
 
The excision and inversion reactions occur between sites within the same 
molecule of DNA (intramolecular recombination). The excision (resolution) 
reaction is carried out between two sites which are in direct (head to tail) 
orientation.  Inversion occurs when the sites are instead present in indirect 
(head to head) repeat as shown in Figure 1.1.  
 
Integration occurs if recombination takes place between different molecules of 
DNA (intermolecular recombination), as long as one or both of the DNA 
molecules are circular (Stark et al. 1992).  
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Figure 1.1: Potential outcomes of recombination 
Integration results from recombination between parallel sites on separate DNA 
molecules.  Excision results from intramolecular recombination between sites 
in a head-to-tail (direct) orientation and inversion from recombination between 
head-to-head (inverted) sites. 
 
 
4 
 
  
Site-specific recombinase enzymes carry out many functions in biological 
systems, including: integration and excision of DNA (e.g. phage genomes), 
transfer of gene cassettes, monomerisation of plasmid multimers and 
resolution of transposition intermediates (Grindley 1994; Grindley et al. 2006). 
These properties make them excellent targets for study as potential tools for 
genetic engineering.  
 
 
1.2   Types of recombinase 
 
There are two main families of recombinase; tyrosine and serine 
recombinases, named according to the amino acid (aa) residue in their 
catalytic domain which acts as a nucleophile, forming a covalent protein-DNA 
linkage during the recombination reaction, which shall be discussed below. 
Both of these recombinase families use their own distinct mechanism of 
recombination (Grindley et al. 2006).  
 
The site-specific recombination reaction involves recognition of and binding to 
specific DNA sites by a recombinase protein, followed by synapsis, cleavage 
of DNA and displacement of a hydroxyl group on the DNA backbone by a 
nucleophile on a side chain of the recombinase. The mechanisms for tyrosine 
and serine recombinases differ.  
 
 
1.2.i   Tyrosine recombinases 
 
Tyrosine family recombinases, including Cre (from the Escherichia coli 
bacteriophage P1) and Flp (from Saccharomyces cerevisiae), use an active 
site tyrosine to create a transient covalent phospho-tyrosine linkage to a 
scissile phosphate on the DNA backbone. Tyrosine recombinases make a 
single stranded cut on both molecules of DNA, creating a 3’ phospho-tyrosine 
bond and leaving a free 5’ OH. Each free 5’ OH then attacks the phospho- 
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tyrosine linkage on the opposite DNA molecule and a Holliday junction 
intermediate is formed. The same process is then repeated on the other pair 
of strands. Following this second round of strand exchange, two recombinant 
molecules are formed and the recombinase subunits dissociate as shown in 
figure 1.2 (Grindley et al. 2006). 
 
 
1.2.ii   Serine recombinases 
 
Serine recombinases make a double strand break at the crossover site in 
each parental DNA duplex; the active site serines of two subunits bound to 
each site attack the DNA, forming a transient double-strand break, with each 
5’ end linked to the recombinase via a phospho-serine linkage. Following 
strand exchange the strands are re-ligated and a new recombinant molecule 
is formed, as illustrated in figure 1.3 (Stark and Boocock 1995; Grindley 2002; 
Grindley et al. 2006).       
 
In many systems, including those of Tn3 and Sin to be studied here and the 
related  resolvase, the site-specific recombination reaction is tightly 
regulated to ensure that the appropriate forward reaction is carried out 
(Grindley et al. 2002). This control is in the form of regulatory subunits which 
are required to form the synapse necessary for recombination to occur in the 
WT system. These regulatory subunits bind to the accessory site DNA to 
regulate the synapsis of the WT recombinase.   
 
‘Activated’ mutants of resolvase have been isolated, which promote 
recombination at site I in the absence of the accessory-sites which are usually 
required as will be discussed later in this chapter, (Arnold et al 1999, Burke et 
al 2004, Rowland et al 2009). Such mutants are invaluable tools for the study 
of protein-DNA interactions at site I. The research carried out for this study 
utilises two such mutants, Sin Q115R (single mutant) and Tn3 NM (multiple 
mutant; R2A, E56K, G101S, D102Y, M103I, Q105L) (Rowland et al. 2009; 
Burke et al. 2004; Olorunniji et al. 2008).  
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The resolvases discussed in this section are related members of the Serine 
recombinase family.  resolvase and Tn3 resolvase are closely related, with 
78.5% sequence identity, Sin is a more distant relative, with  32% identity to 
Tn3 and 31% identity to  (see figure 1.4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Alignment of , Tn3 and Sin 
(A) Sequence alignment showing identity of the resolvases discussed in this work. 
Tn3 and  have 78.5% sequence identity, Tn3 and Sin have 32% identity and  
and Sin have 31% identity. Alignment was performed using Clustal Omega multiple 
sequence alignment software, EMBL-EBI.  (B) Structural comparison of Sin(right)  
and  (left) resolvases, made using crystal structures 2R0Q and 1GDT respectively.  
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1.3   Tn3 resolvase   
 
Tn3 resolvase is a member of the serine recombinase family, encoded by the 
bacterial transposon Tn3, which also encodes -lactamase (bla) and 
transposase (tnpA) genes (figure 1.5). The biological function of Tn3 
resolvase in nature is the resolution of co-integrates formed during replicative 
transposition of its transposon (Grindley et al. 2002). 
 
Each subunit of Tn3 and the related  gammadelta resolvase has a structure 
consisting of a catalytic N-terminal domain, E-helix, AT hook DNA binding 
motif and C-Terminal DNA-binding domain (figure 1.6) (Yang and Steitz 
1995). The structure of resolvase and the importance of the structure for the 
protein’s function will be discussed further in section 1.3.ii   
 
 
1.3.i Recombination by Tn3 resolvase 
 
Resolvase-mediated recombination requires an identical pair of DNA sites, 
known as ‘res’. The full Tn3 res site is 114 bp in length, consisting of a 28 bp 
catalytic site (site I) which has a 12 bp head-to-head repeat sequence at each 
end and two regulatory sites, site II and site III, of 34 bp and 25 bp in length 
respectively. A 22 bp spacer separates sites I and II, and a 5 bp spacer 
separates sites II and III (see figure 1.7) (Burke et al. 2004). Two catalytic 
subunits of Tn3 resolvase bind to each of the two site I’s as dimers, with four 
more resolvase subunits (two dimers) binding to sites II and III; thus the fully 
assembled synapse consists of two full res sites bound by a total of twelve 
subunits of resolvase.  
 
Resolution of a circular plasmid by Tn3 resolvase yields a 2-node catenane 
product as seen in figure 1.7. Regulatory dimers bound at sites II and III in the  
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Figure 1.6: Structure of a  resolvase dimer bound to DNA  
(A) Crystal structure of  resolvase, showing the N-terminal catalytic  domain 
(green) connected to the E-Helix (blue), linked by an extended linker region (yellow 
with AT-hook DNA binding motif sitting in the minor groove shown as spheres) to a 
helix-turn-helix DNA-binding domain (red) bound to DNA (grey). The position of the 
catalytic nucleophile S10 is shown.  Image created using 1GDT crystal structure 
from PDB (Yang & Steitz 1995).   
(B) Cartoon highlighting the functional regions of the structure and showing the 2,3’ 
interface (dark green oval) between the catalytic and regulatory subunits, dimer 
interface (dashed line) and synaptic interface (dotted line).  
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wild-type (WT) system promote the pairing of resolvase dimers bound at site 
I. Interactions between the sites promote stability within the structure and 
regulate recombination. Interactions between site I and site III create a dimer-
dimer interaction which promotes catalysis at site I. Interactions between the 
two res sites trap three negative supercoils as can be seen in figure 1.7, thus 
storing energy for use in the recombination reaction (Stark and Boocock 
1995; Burke et al 2004; Grindley et al. 2006).  
 
 
1.3.ii  The structure of Tn3/ resolvase 
 
Much of what is known about the domain structure and function of the serine 
recombinases has come from the archetypal  resolvase, which has very 
similar sequence to Tn3 (78.5% sequence identity). The structure of  
resolvase and the related Tn3 and Sin recombinases have been revealed by 
a number of crystal structures (Yang and Steitz 1995; Li et al. 2005; Mouw et 
al. 2008; Keenholtz et al. 2011). These serine recombinases have a structure 
consisting of an N-terminal catalytic domain ( residues 1-100), an extended 
E-helix ( residues 101- 120) and E-helix arm ( residues 121-137) 
connected by a short linker ( residues 138-148) to the C-terminal DNA 
binding domain as shown in figure 1.5.  The catalytic domain is made up of 
four -helices (A, B, C and D) with -sheet between D and the other -
helices.  Residues R2 and E56 within the catalytic domain are involved in the 
2-3’ interface between the catalytic site I subunits and the regulatory subunits 
at site III for regulation of the WT synapse (Sarkis et al. 2001). Residues Y6, 
R8, S10, D36, R68 and R71 within the catalytic domain are highly conserved 
and are important for catalysis, as mutation of these residues is detrimental to 
catalysis by Tn3 at site I (Olorunniji and Stark 2009).  
 
The E-helix is involved in formation of dimer interactions, with hydrophobic 
residues forming interactions between the E-helices of each subunit, 
stabilising the dimer structure and positioning the catalytic domain relative to 
 
 
14 
 
the DNA.  The E-helix remains structured even in the absence of DNA (Rice 
and Steitz 1994). The ‘arm’ region of the E-helix is disordered in the absence 
of DNA. This region forms interactions within the minor groove of the DNA 
and assists in positioning of the CTD (figure 1.5). The extended linker region 
( residues 138-148) contains the conserved ‘GR’ A-T hook motif (amino 
acids 141 and 142) and forms interactions within the minor groove at a 
conserved AT base pair. The DNA-binding domain has three -helices (F, 
G and H) which surround a conserved hydrophobic core. The G and H 
helices form a helix-turn-helix motif which confers DNA recognition for the 
motifs at each end of res site I and the regulatory sites II and III via hydrogen 
bonds and hydrophobic interactions with specific nucleotides. Hydrogen 
bonds and salt bridges are formed between phosphate residues in the DNA 
backbone and residues R148, S162, A171, T174, Y176 and K177. This acts 
to anchor the CTD within the major groove. Further base-specific interactions 
are formed between the DNA and residues R172, S173, Y176 and K177.   
 
Two models were proposed for the synaptic interactions of serine resolvases 
and DNA at the crossover sites; namely, the ‘DNA in’ and ‘DNA out’ models. 
The ‘DNA in’ model proposed that the DNA is held at the inside of the 
complex with the resolvase subunits on the outside, the ‘DNA-out’ model 
proposed that the resolvase subunits are in the centre, with the DNA on the 
outside. The DNA-out arrangement was determined by Nöllmann and 
colleagues (Nöllmann et al. 2004) crystal structures obtained for  resolvase 
and Sin resolvase also show that this interaction fits with the ‘DNA out’ model 
(Burke et al 2004; Li et al. 2005; Rowland et al. 2009). The currently favoured 
model for the mechanism of the recombination reaction at the crossover site 
is the ‘subunit rotation’ model. This model, suggested by biochemical and 
topological data and supported by crystal structure data, hypothesises that 
during recombination the DNA strands are cleaved and then one half of the 
intermediate protein-DNA complex rotates 180° relative to the other at the flat 
interface of hydrophobic residues (Grindley et al. 2006) which can be seen at 
the E-helix interface in crystal structures of recombinase such as that of  
resolvase, as shown in Figure 1.8.  
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Sin resolvase is a member of a group of serine recombinases which are 
encoded by large Staphylococcus plasmids. It was initially identified as a  
member of the family by Paulsen and colleagues based on sequence analysis 
(Paulsen et al 1994); its natural role is to reduce plasmid multimers to  
monomers. This increases plasmid stability, as monomers are maintained at 
higher copy number in cells than multimers, thus reducing the risk of the  
plasmid being lost. The resolution product produced by Sin recombinase, like 
that of Tn3, is a pair of catenated DNA circles.  
Sin resolvase is structurally very similar to the previously described Tn3/ 
resolvases.  resolvase has 31%sequence identity to Sin. The crystal 
structure of DNA-free Q115R Sin (Keenholtz et al. 2011) shows the structure 
of the catalytic domain and E-helix (residues 1-124); however the C-terminus 
is not revealed. No crystal structure currently exists showing DNA-bound Sin 
at site I, although a crystal structure is available which reveals a DNA-bound 
tetramer at site II (figure 1.9) (Mouw et al. 2008).  The structure of Sin will be 
further discussed in section 1.4.ii. 
 
 
1.4.i Recombination by Sin 
 
Sin has an 86 bp res site, (resH)  with a 30 bp catalytic site I, separated by a 
31 bp spacer containing a HU binding site from its 25 bp site II (figure 1.10). 
Site I is made up of a head-to-head repeat sequence, whereas site II is 
arranged in a head-to-tail repeat. Sin-mediated recombination requires the 
binding of a DNA bending protein such as HU from Staphylococcus aureus or 
HBsu from Bacillus subtilis (Rowland et al 2005, Rowand et al 2006; Grindley 
et al 2006). The assembly of the Sin synaptosome, like that of Tn3 resolvase, 
traps three negative supercoils. The strand-exchange reaction is chemically 
isoenergetic and thus has no necessity for a high energy co-factor.  Activated 
Sin mutants such as I100T and Q115R allow interactions of the catalytic  
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Figure 1.9: Structure of a Sin resolvase bound to DNA (resH site II)  
(A) Sequence of resH site II  (B) A dimer of Sin resolvase bound to the regulatory site II. Site 
II, unlike site I, has a head to tail orientation of the Sin CTD-binding motifs. Synapsis at site II 
is mediated by an interface between the DNA-binding domains, as shown in the tetramer 
structure (C). Position of catalytic serine (S9) isindicated. Images were created using the 
2R0q crystal structure (Mouw et al 2008). 
A 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
C 
CGTATGATTAGGGTGTATATTAATT 
GCATACTAATCCCACATATAATTAA 
Site II a    Site II b 
S9 
S9 
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tetramer at Site I to be studied in the absence of the accessory sites and 
DNA-bending protein (Rowland et al 2005; Mouw et al 2010). The work 
carried out in this study utilises the Q115R Sin mutant.  
 
 
1.4.ii  The structure of Sin resolvase 
Crystal structure data for the activated mutant of Sin (Q115R) (Keenholtz et al 
2011) revealed a tetrameric architecture of catalytic domains similar to that 
seen in the structure of  resolvase (Li et al 2005). Sin shares the catalytic 
domain structure of four -helices (A-D) and -sheet structure connected by a 
short linker to an extended E-helix as described for /Tn3 resolvase in 
section 1.3.ii. One of the -sheet structures in  resolvase is replaced in Sin 
with a further -helix, termed D’. This D’-helix is poorly ordered in the crystals, 
indicating that it has flexibility and supporting the hypothesis that this acts as 
a ‘hinge’, permitting the E-helices to move relative to the catalytic domains. 
Residues F52 and R54 of the catalytic domain form the Sin equivalent of the 
 resolvase 2-3’ interface between sites I and III (Mouw et al. 2008) which 
connects dimers of resolvase and  is essential for wild-type resolvase to 
assemble the synapse of two res sites.  
This Sin structure does not reveal the DNA-binding domain structure. 
However, the homology shared by Sin and Tn3/ resolvases means that the 
structure formed by Sin at site I can be extrapolated, by docking of the Sin 
structure (Keenholtz et al. 2011) to the DNA-bound CTDs of the  structure 
(Yang and Steitz 1995). Such a model is shown in figure 1.11.   
 
The activated Sin Q115R crystal structure shows the tetramer in a different 
rotational state than has previously been seen in structures of other 
resolvases. The Sin E-helix has an insertion at the N-terminal end, making it 
one turn longer relative to the  resolvase structure and altering the angle of 
the E-helices of Sin relative to  resolvase (see figure 1.12), as a result of 
which, the cutting dimers of Sin are held further apart than those of  
resolvase.  
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Figure 1.11: Model of Sin activated mutant dimer bound to site I 
This model shows Sin (blue) residues 1-124 (crystal structure 3PKZ) docked by rigid body 
docking to  resolvase CTD (green) (crystal structure 1GDT) bound at site I. This image 
shows half of a hypothetical catalytic tetramer, the Sin shown is an activated mutant from a 
tetramer structure. Image created using 3PKZ and 1GDT crystal structures from PDB 
(Keenholtz et al 2011, Yang and Steitz 1995). 
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A 
 
 
 
 
 
 
 
 
 
 
 
B 
Figure 1.12: The E-helices of Sin and  
(A) Catalytic domains and E-helices of DNA-free Sin tetramer (left) and E-helices only 
(right) (3PKZ). (B) Catalytic domains and E-helices of DNA-bound  tetramer (left) and 
E-helices only (right) (1ZR4).  The altered rotational state of Sin relative to  leads to 
an altered angle of E-helices. Figure made using 3PKZ and 1ZR4 crystal structures 
(Keenholtz et al 2011, Li et al 2005) 
 
 
22 
 
A crystal structure of the regulatory Sin tetramer bound to two copies of site II 
(Mouw et al. 2008) (illustrated in figure 1.9) showed at high resolution the  
catalytic N-terminal domain, helix-turn-helix (H-T-H) DNA-binding C-terminal 
domain and the intervening extended E-helix.  This regulatory structure 
reveals asymmetry in the Sin dimers. This asymmetry permits the docking of 
the CTDs to the head-to-tail DNA sub-sites in the configuration seen in the 
crystal structure. In this structure, the catalytic serines of each monomer are 
partially blocked from the DNA by the positioning of the E-helix of the other 
monomer, so that the protein is catalytically inactive at site II.   
 
The E-helix region of resolvase is involved in formation of dimer interactions, 
with interactions between the E-helices stabilising the dimer structure and 
positioning the catalytic domain relative to the DNA.  The modularity of 
resolvase offers a way to study the effect of the E-helix on synapsis and DNA 
binding, as the catalytic domain can be removed, yielding a truncated variant. 
Such truncated variants termed ‘tadpoles’ shall be discussed in detail in 
chapter 3.  
 
 
1.5   Genetic applications of site specific recombinases 
 
Targeted  modification  of  the  genome  has  a  variety  of  applications  in  
research, medicine,  and  biotechnology.  Site-specific recombinases are 
important tools in these areas. Site-specific  recombinases  allow  the  precise  
integration of  open  reading  frames  encoding  pharmaceutically  relevant  
proteins  into  specific  gene loci  in  cell  lines  and  transgenic  animals (Kolb 
2004).     
 
Since site specific recombination typically occurs between DNA sequences 
which have evolved very specifically along with a resolvase enzyme to obtain 
optimum efficiency, they have very sequence specific targeting. In order for 
recombinases to be useful as tools for genome editing, it is necessary to alter  
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the protein to change its natural sequence selectivity. This can be achieved 
by directed evolution to achieve recognition of pseudo-sites or by domain 
swapping for recognition of different sites. Directed evolution has been used 
successfully with the large serine recombinase C31 integrase, altering its 
specificity to target pseudo attP sites in the human genome (Thyagarajan et 
al. 2008).  
 
Due to the modular nature of resolvase, the DNA-binding and catalytic 
domains can be separated into distinct domains. This means that the DNA- 
binding domain can be removed and swapped for that of another protein to 
give targeting to a different site.  Domain swapping experiments, creating 
chimeric proteins with the catalytic activities of the chosen catalytic domain 
and the DNA-targeting of the chosen DBD have been carried out with 
members of the serine recombinase family. Schneider et al. demonstrated 
that the DNA-binding domain of Gin invertase could be replaced with that of 
Tn3 resolvase, creating a chimeric protein which interestingly was able to 
function as a resolvase, but not as an invertase (Schneider et al. 2000). 
Domain swapping experiments have also been carried out with Tn3 
resolvase, in which the DNA binding domain of Tn3 resolvase was replaced 
with a zinc finger DNA binding domain (Akopian et al. 2003, Prorocic et al. 
2011) additionally, the Gin invertase DBD was replaced with that of a 
transcription activator like effector (TALE) binding domain (Mercer et al. 
2013). Zinc finger recombinases (ZFRs) and transcription activator like 
effector recombinases (TALERs) will be discussed in more detail in sections 
1.7.iv and 1.7.v respectively.  
 
This recombinase modularity also means that the DNA-binding domain of 
resolvase is able to bind in the absence of the catalytic domains, a property 
which allows closer examination of the E-helix domain, as will be discussed in 
chapter 3. 
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1.6   Other methods of genome editing  
 
Methods of genome editing such as alteration of gene expression by 
chromosomal integration of DNA by homologous recombination are limited 
and can have off-target effects. Integration at random loci in the absence of 
targeting is inefficient and the gene may be subjected to locus-specific 
epigenetic effects which may down-regulate or silence it (Pannell & Ellis 
2001). Insertion at certain positions has the potential to disrupt local genes 
and cause detrimental effects.  Gene knockout via HR can be prone to off-
target effects, and can be inefficient dependent on cell-type (Smith 2001). 
Additionally, as the HR system is essential for cellular functions, its use for 
engineering purposes may negatively impact on local genes and have 
disruptive effects on local gene expression (Akopian and Stark 2005).  
 
Addition of genes into mammalian cell lines is of interest for medicine, 
synthetic biology, engineering of cell systems and gene function studies. 
Some methods of chromosomal gene insertion involve random integration 
within the genome. These random insertions can have potentially damaging 
effects, as seen in clinical gene therapy trials, in which the insertion of a viral 
vector containing a transgene with a strong viral promoter into the genome 
proximal to proto-oncogenes has led to de-regulation and cellular clonal 
expansion (Ott et al. 2006, Fischer et al. 2010, Cavazzana-Calvo et al. 2010). 
 
Transposon-derived insertion vectors like Piggybac and Sleeping Beauty are 
however useful for other applications such as identification of potential proto-
oncogenes in murine models, although their uses for gene therapy are limited 
by their non-specific insertions (Collier et al. 2005, Ivics et al. 2007, Rad et al. 
2010). 
 
The focus of this work is the study of DNA targeting by members of the site-
specific serine recombinase family. Previous work carried out by the Stark 
group led to the development of zinc finger recombinases (ZFRs). This work 
will discuss the creation of a similar chimeric protein, a TALE recombinase 
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(TALER). However, it is important to note that there are several other 
methods of genome editing available, including the zinc finger nucleases 
(ZFNs), the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/Cas 9 system and Transcription Activator-Like Effector Nucleases 
(TALENs), which shall be discussed briefly. 
 
1.6.i The CRISPR/Cas System 
 
An emerging alternative to the zinc finger and TALE DNA targeting 
mechanisms is the CRISPR/Cas system. The CRISPR system is a bacterial 
acquired immunity system protecting against invading foreign DNA by RNA-
guided DNA cleavage (Barrangou et al. 2007).  
 
There are three main types of CRISPR/Cas system, with many more sub-
types. The most commonly utilised of these is the type II system. There are 
three main steps in the type II system; adaptation, biogenesis and 
interference. During adaptation, new spacers are incorporated into the 
CRISPR locus; these spacers are acquired from protospacer sequence in 
invading DNA. This CRISPR locus is made up of direct repeats, separated by 
the spacer sequences. Biogenesis is the process of transcription of this 
CRISPR locus, forming pre-crRNA primary transcript, which is then 
processed to form short crRNAs. These crRNAs associate with CRISPR 
associated (Cas) proteins and these CRISPR/Cas complexes provide 
immunity against infection by plasmids and bacteriophages. Upon recognition 
of a complementary protospacer and PAM DNA sequence in the invading 
DNA, the CRISPR/Cas complex blocks replication of foreign DNA and 
initiates DNA cleavage (Figure 1.13) (Samson et al. 2013). 
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The CRISPR/Cas system has great potential for targeting, as re-design of the 
crRNA can allow targeting of Cas cleavage to a desired site. Similar to zinc 
fingers and TALEs, Cas9, the most commonly used type II Cas protein has 
two nuclease domains (RuvC and HNH) and as been engineered to act as an 
endonuclease and as a nickase for RNA-guided site-specific DNA cleavage 
(Cong et al. 2013).  
 
 
1.6.ii Zinc Finger Nucleases  
 
Engineered nucleases, using the cleavage domain of a nuclease and a 
sequence-specific DNA-binding domain, have been developed for ‘genome 
editing’, creating targeted double strand breaks which stimulate cellular DNA 
repair mechanisms such as Homology Directed Repair (HDR) and Non-
Homologous End Joining (NHEJ), with the targeting specificity conferred by 
zinc finger or TALE DNA binding domains. 
 
The zinc finger Cys2-His2 domain is one of the most common motifs in 
eukaryotes. Each finger is made up of approximately 30 amino acids in a 
conserved  configuration. 3 bp of DNA in the major groove of the DNA is 
recognised by residues on the surface of the -helix, with each finger 
therefore giving specificity for a specific triplet of bases (Beerli and Barbas 
2002).  
 
Due to the modular nature of zinc finger proteins, different sequence 
selectivity can be designed by swapping the fingers. Artificial zinc finger 
domains with the ability to recognise 9-18 bp of DNA have been created 
Dreier et al. 2001, Dreier et al. 2005). The development of such artificial zinc 
finger domains greatly increases their specificity, as 18 bp of DNA recognition 
theoretically confers specificity for 68 billion base pairs of DNA (418), meaning 
that genomic targeting became possible.    
 
 
 
 
28 
 
 
Zinc finger assembly can now be carried out using a zinc finger library (Beerli 
and Barbas 2002) or by other methods, such as the selection-based 
randomised approach, known as Oligomerized Pool Engineering (OPEN) 
(Maeder et al. 2008).  
 
Traditionally, the process of gene replacement, inactivation or insertion has 
utilised homologous recombination techniques. However, homologous 
recombination is carried out inefficiently in mammalian cells. Chimeric 
nucleases, such as the ZFNs have been used to increase this efficiency by 
targeting double-strand breaks to a specific locus (Moehle et al. 2007).  
 
The double-stranded cleavage of DNA by site specific nucleases can lead to 
HDR, which can be used for gene correction or NHEJ (Figure 1.14). NHEJ is 
error-prone by nature and as such introduces small insertions or deletions. 
This can cause frame-shift mutations. In order to negate the effects of this, 
nickases, nucleases engineered to nick the DNA instead of causing double-
strand breaks have been developed, which stimulate HDR without promoting 
NHEJ (Kim et al. 2012 and Gaj et al. 2012). 
 
 
1.6.iii TALE Nucleases (TALENs) 
 
An addition to the available DNA-binding domains for creation of chimeric 
nucleases and recombinases is the Transcription Activator-Like Effector 
(TALE) family of proteins. TALEs are found in nature in plant pathogens 
(Xanthomonas sp.) where they act as transcription factors to directly 
modulate host gene expression. They have DNA-binding domains which 
consist of 33-35 amino acid repeats (typically 34 amino acids), each of which 
confers recognition to a single base pair of DNA (figure 1.15) (Mak et al. 
2012; Deng et al. 2012).  
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NHEJ                                   HDR 
DSB 
Gene Disruption                                         Gene Correction 
Figure 1.14: Possible outcomes of nuclease DNA targeting 
Nuclease-based DNA targeting can either lead to Non-Homologous End Joining 
(NHEJ) or Homology Directed Repair (HDR).  NHEJ naturally leads to small 
insertions or deletions often causing gene disruption. HDR in nature uses a DNA 
molecule with sequence homology to repair double strand breaks. Introduction of a 
plasmid with flanking homologous regions can be used for gene correction.  
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The amino acids at positions 12 and 13 of the repeats form the repeat 
variable di-residue (RVD), a hyper-variable region which is responsible for 
sequence recognition. The amino acid at position 13 of each repeat is 
involved in recognition of the DNA, while the amino acid at position 12 is 
involved in stabilising the protein structure by interactions with the 
neighbouring repeat (Streubel et al. 2012). The sequence which is recognised 
by these RVDs can be altered by altering the order of these RVD containing 
repeats.  
 
The RVD nucleotide recognition code has been studied, and as such, the 
nature of DNA binding by RVDs is now better understood. The four most 
common RVDs found in nature are: HD, NG, NI and NN (which recognize C, 
T, A and G/A respectively). In 2009, studies of the TAL recognition code 
identified the sequence selectivity by common and rare RVDs highlighting the 
sequence recognition selectivity by the repeats (Boch et al. 2009, Moscou & 
Bogdanove 2009).  
 
The complete modularity of these TAL repeat domains is unique amongst the 
commonly studied DNA-binding domains, which can have positional 
constraints for modular assembly, as in other cases such as zinc finger 
domains, neighbouring fingers can have an effect on sequence recognition of 
the adjacent finger (Miller et al. 2008), meaning that certain sequences are 
more efficiently bound than others, and some sequences cannot be targeted.  
Zinc finger domains are costly and time consuming to develop and have 
sequence limitations which the TALs do not have, with certain sequences for 
which no compatible zinc finger binding domains are available. The TALEs by 
comparison are relatively simple to construct and to customise, making them 
potentially very useful as tools for genome engineering and for synthetic 
biology purposes (Zhang et al. 2011; Mussolino et al. 2012).  
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Figure 1.15: TALE Structure 
(A) TAL Effector domain organisation, showing the DNA-binding domain repeats (red boxes) with 
RVDs from the TALE DBD used in this study and the DNA sequence recognised by it (grey), the 
nuclear localisation domain (yellow) and activation domain (brown) which are required for natural 
function.  (B) Crystal structure of a TALE PthXo1; (PDB ID: 3UGM) bound to DNA, with repeat 
finger highlighted in different colours. The fingers can be seen to wrap in a spiral around the DNA 
with the RVD positions 12 and 13 at the centre of the structure interacting specifically with the 
DNA (C) Individual TAL fingers bound specifically to a specific nucleotide, according to the repeat 
variable di-residue (RVD) present at positions 12 and 13 of the repeat., and recognition of 
preceding ‘T’ by the tryptophan (w) residue in finger -1 (yellow). 
HD = C NI = A NN = G 
T 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
C 
W = T 
Finger     -1 0  1    2    3    4    5    6    7    8    9   10   11  12   13   14   15  16 
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Although the TAL effectors are largely free from many of the constraints 
posed by other DNA-binding domains such as zinc fingers, they do have one 
limitation, namely, the necessity of the recognition sequence to have a ‘T’ 
base 5’ of the recognition sequence. This highly conserved nucleotide is 
believed to interact with the TAL ‘0’ and ‘-1’ repeats, improper repeat fingers 
N-terminal of the RVD-containing canonical repeats, as demonstrated by Mak 
and colleagues, whose 2012 crystal structure of the PthXo1 TALE shows that 
a tryptophan in the ‘-1’ finger N-terminal of the near-identical RVD containing 
repeats is located near enough to this 5’ T base to interact with it (Mak et al. 
2012). 
 
The 5’ T has been shown to be necessary for efficient TALE binding and adds 
an undesirable restriction to the use of TALE domains for site-specific DNA 
targeting.  Tsuji and colleagues recently examined the possibility of removing 
this requirement for the 5’ T by targeted mutagenesis of the ‘-1’ finger of the 
TALE (Tsuji et al. 2013). They made single point mutations, changing the 
tryptophan in the ‘-1’ finger to other amino acids, and carried out targeted 
mutagenesis of four amino acids in the loop region of this finger. They 
showed that through directed evolution of this region, they were able to 
remove the T constraint from the 5’ end. Their work also indicated that the 
tryptophan is important to the binding of the T, as single point mutations of 
this residue did not allow the binding of sequences with no 5’ T, but did 
prevent efficient binding to the 5’ T substrate.     
 
TALEs, like zinc fingers have been used to construct hybrid nucleases 
(Christian et al. 2010), transcriptional activators (Mussolino et al. 2011) and  
recombinases (Mercer et al. 2012). As TALE modules have single base pair 
recognition, they have greater flexibility for construction; however, initially 
their highly repetitive nature was problematic for synthesis and assembly. 
Methods have now been developed which allow easy assembly of custom 
TALE arrays (Cermak et al. 2011, Reyon et al. 2012, Briggs et al. 2012, 
Schmid-Burgk et al. 2013).  The development of new, efficient TALE 
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assembly methods has facilitated the assembly of libraries of TALE arrays, 
such as the recently created library of TALENs which is able to target 18,740 
human protein coding genes (Kim et al. 2013).  
 
ZFNs and TALENs have been successfully used for therapeutic applications, 
such as the use of ZFNs to correct mutations associated with Severe 
Combined Immunodeficiency (SCID), sickle cell disease and haemophilia-B 
(Urnov et al. 2005, Sebastiano et al. 2011 and Li et al. 2011) and the use of 
TALENs in targeted correction of the sickle cell disease-causing mutation in 
the -globin gene in human cells (Sun et al. 2012).   
 
 
1.6.iv Zinc finger recombinases 
 
Zinc finger recombinases (ZFRs) are site-specific recombinases with the 
catalytic domain from resolvase proteins such as the Tn3 and Sin resolvases, 
fused to the DNA binding domain of a zinc finger protein such as the mouse 
transcription factor Zif268. Designer recombinases such as ZFRs, like the 
ZFNs previously discussed, have great potential for use in biotechnology, 
gene therapy and experimental genetics (Urnov et al. 2005, Sebastiano et al. 
2011 and Li et al. 2011).  
 
The development of ‘activated’ serine recombinases discussed in sections 1.2 
and 1.4, which act on their catalytic site without the requirement for the 
accessory site proteins have been essential for the creation and success of 
chimeric proteins such as the ZFRs. ZFRs with activated Tn3 resolvase and 
Gin invertase domains have been shown to be functionally active with in 
human cell lines (Gordley et al. 2007 & 2009, Gersbach et al. 2011, Gaj et al. 
2013). Such experiments indicate that despite the limitations which have been 
discussed, there is a great deal of potential for these types of chimeric 
recombinases for applications such as genomic editing.  
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Site-specific recombinases have been successfully used as molecular biology 
tools to specifically carry out integration and excision of DNA sequences. The 
usefulness of natural recombinases however is limited by the necessity to 
either rely on the presence of pseudo-sites in genomic DNA or to first 
introduce cognate recognition sites into the genome prior to expression of the 
recombinase, for example by HR.   
 
The zinc finger DNA-binding domain (DBD) is a small DNA-binding domain, 
consisting of three fingers, each of which typically confers recognition to 3 bp 
of DNA, giving recognition of a 9 bp DNA sequence. ZFRs are chimeric 
proteins with the DNA binding domain from a zinc finger protein fused to the 
activated mutant catalytic domain of a site- specific recombinase such as Tn3 
resolvase.  Such ZFRs have been shown to recombine specially designed ‘Z-
sites’ with the zinc finger binding site flanking the natural crossover site of 
resolvase in vivo and in vitro (Akopian et al. 2003).  
 
Chimeric proteins such as ZFRs, which can have their DNA-binding domains 
altered to bind to many different sequences, reduce this limitation, allowing 
targeting to be carried out to a wider variety of sequences. Previous work 
carried out in our lab showed that a ZFR with an activated mutant version of 
the Tn3 resolvase catalytic domain could be efficiently targeted to specifically 
designed ‘Z-sites’ (Akopian et al. 2003, Prorocic et al. 2011).   
 
A limitation of the ZFRs is the specificity for the centre of the target DNA 
sequence, which is conferred by the resolvase domain. However, directed 
evolution of recombinases has been carried out to give these proteins activity 
at sites which resemble, but are not identical to their original cognate site 
(Sirk et al. 2014). Previously in the Stark lab Tn3-ZFRs were successfully 
targeted to Z-sites containing the sequences of the bovine -casein gene, a 
potentially useful target for gene integration (Proudfoot et al. 2011).  
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1.6.v TALE Recombinases (TALERs) 
 
ZFRs have been shown to be useful and effective for targeting to certain 
sites. However they suffer from issues such as a lack of high-affinity 
recognition of all DNA triplets, imperfect modularity, and difficulty of 
construction, limiting their usefulness for genome engineering. The 
emergence of TALEs and the demonstration of their effectiveness in targeting 
TALENs led to the design and creation of TALE recombinases (TALERs).   
 
TALERs, utilising the specific DNA-binding capabilities of TALEs and the 
catalytic capabilities of activated recombinase mutants, have the potential to 
surpass the ZFRs, as the TALE domains do not share the above limitations 
for sequence selectivity and thus can potentially be targeted directly to more 
genomic sequences. The creation of a TALER with the catalytic domain of an 
activated Tn3 resolvase will be discussed in chapter 4.  
 
 
1.7   Project aims 
 
Site-specific recombination, using a zinc finger or TALE DNA-binding domain 
fused to the C-terminus of the catalytic domain of a serine recombinase in 
place of its natural helix-turn-helix domain has the potential to specifically 
carry out recombination at a desired locus. As the site-specific recombinases 
carry out all of the steps required for DNA cleavage, rearrangement and re-
ligation, they have an advantage over the nucleases, which rely on the 
cellular repair machinery to repair the double-strand breaks created by the 
nuclease domain. This gives the recombinases potentially higher activity with 
fewer off-target effects than their nuclease counterparts.  However, in order 
for recombinase proteins to have optimal functionality, it is important to have 
a very detailed knowledge of the protein, its structure and functions.   
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This project examined the structure and functions of members of the serine 
recombinase family, including the Tn3 and Sin family recombinases, in order 
to determine which regions of these proteins are involved in processes such 
as DNA binding, dimer interactions and synapsis. A further goal of this project 
was the creation of a chimeric TALER with specific activity targeted to a 
chosen DNA site.  
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Chapter 2: Materials and Methods  
 
 
2.1 Bacterial Strains  
 
Both of the Escherichia coli strains used in this study are derivatives of the K-
12 strain. Their names, genotypes and original sources are given in Table 
2.1.  
 
Bacterial Strain Genotype Source 
DS941 AB1157, recF, lacZM15, lacIq 
Summers and 
Sherratt, 1988 
BL21(DE3)[pLysS] 
Hsd, gal, (cI ts 857, ind1, sam7, ini5, 
lacUV5-T7 gene-1), T7 lysozyme 
expressing plasmid pLysS 
Studier et al 
1990 
 
Table 2.1: Bacterial strains used in this study 
 
 
2.2 Bacterial Growth Media 
 
Liquid cultures of E.coli were grown at 37C in L-Broth (10 g tryptone, 5 g 
yeast extract and 5 g NaCl, made up to 1 L with de-ionised H2O and adjusted 
to pH 7.5 with NaOH). Bacteria were also grown on solid media (L-broth with 
15 g/L agar).  
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2.3 Antibiotics 
 
Antibiotics were typically made up as 500x or 1000x stocks for storage 
purposes, shown in Table 2.2. 
 
 
Antibiotic Stock Concentration Final Concentration 
Ampicillin  
(500x)  
50 mg/ml in H2O 100 g/ml 
Chloramphenicol 
(1000x) 
25 mg/ml in EtOH 25 g/ml 
Kanamycin 
(1000x) 
50 mg/ml in H2O 50 g/ml 
Streptomycin 
(500x) 
50 mg/ml in H2O 50 g/ml 
 
Table 2.2: Antibiotic stock and working concentrations. 
 
2.4 Chemicals 
 
Chemicals used in the assays were purchased from suppliers, as shown in 
Table 2.3 below.  
 
Chemical Source 
General chemicals, organic solvents and 
biochemicals 
Aldrich/Sigma 
Media Difco 
Agarose and acrylamide Biorad 
Radiochemicals Amersham Biosciences 
Restriction enzyme buffers NEB, Roche, Promega 
 
Table 2.3: Chemical reagents utilised in this study and their suppliers. 
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2.5 Gene synthesis 
 
Synthetic constructs for creation of TALER expression plasmids were 
designed and ordered from Life Technologies, GeneArt Gene Synthesis.    
  
 
2.6. Oligonucleotides 
 
All oligonucleotides used in this study for cloning and plasmid construction 
were ordered from Eurofins Genomics (Table 2.4).  
 
 
2.7. Plasmids 
 
Plasmids were constructed by restriction digests and fragment swaps from 
existing plasmids. A list of plasmids created and used is provided in Table 
2.5. Construction methods for groups of expression plasmids are outlined in 
figure 2.1. 
 
Expression plasmids with both high and low levels of expression were used in 
this study, with high-level expression vectors being used for overexpression 
of resolvase proteins for purification and use in in vitro assays and low-level 
expression vectors used for in vivo experiments.  
 
 
2.7.i High-level resolvase expression plasmids 
 
All overexpression plasmids constructed are based on pSA1101 (Arnold et al 
1999). pSA1101 has a ColEI origin of replication, encodes a kanamycin 
resistance marker and contains an inducible T7 promoter, which induces 
overexpression of resolvase cloned in between NdeI and Asp718 restriction 
sites in the pSA1101 backbone (figure 2.1). 
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
M13 uni 
(-43) 
23 bp AGGGTTTTCCCAGTCACGACGTT Sequencing primer 
M13 rev 
(-49) 
24 bp GAGCGGATAACAATTTCACACAGG Sequencing primer 
T7 20 bp TAATACGACTCACTATAGGG Sequencing primer 
MB67 58 bp 
CATGCCGGGAGCTCACTAGTATGTATGATTAGGGTATACCCTAATCATA
CAAAGAATT 
To introduce symmetrised (To RHS) 
Sin Site I 
MB71 58 bp 
CTAGAATTCTTTGTATGATTAGGGTATACCCTAATCATACATACTAGTGA
GCTCCCGG 
To introduce symmetrised (To RHS) 
Sin Site I 
MB68 58 bp 
CATGCCGGGAGCTCACTAGTATGTATGATTATATTATAATATAATCATAC
AAAGAATT 
To introduce symmetrised (To RHS) 
Tn3 Site I 
MB72 58 bp 
CTAGAATTCTTTGTATGATTATATTATAATATAATCATACATACTAGT 
GAGCTCCCGG 
To introduce symmetrised (To RHS) 
Tn3 Site I 
MB70 58 bp 
CATGCCGGGAGCTCACTAGTAAACGGCGGCTTTACGTACCCTAAT 
CATACAAAGAATT 
To introduce symmetrised (To RHS) 
 Sin Site I 
MB74 58 bp 
CTAGAATTCTTTGTATGATTAGGGTACGTAAAGCCGCCGTTTACTAGTG
AGCTCCCGG 
To introduce symmetrised (To RHS) 
 Sin Site I 
SEH1-T 54 bp TATGAACCCATTACTAGATAAATTCATGAAAGACCTAATCATTCAAATATTAGC 
To introduce truncation of Sin NTD 
before residue 101 
SEH1-B 56 bp 
CATGGCTAATATTTGAATGATTAGGTCTTTCATGAATTTATCTAGTAATGGGTTC
A 
To introduce truncation of Sin NTD 
before residue 101 
Table 2.4: Oligonucleotides used in this research.    
Oligonucleotides were ordered from MWG as two sequences; top (T) and bottom (B) which were then annealed prior to cloning. 
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
SEH4-T 82 bp 
TCGAACGAATGAGGGCCGACAGGAAGCAAAGCTGAAAGGAATCAAA
TTCGGCCGCCCTTTGCTTTATTCACCGAACGCGAAG 
For insertion of Tn3 E-helix ‘arm’ into 
Sin 
SEH4-B 82 bp 
GATCCTTCGCGTTCGGTGAATAAAGCAAAGGGCGGCCGAATTTGATT
CCTTTCAGCTTTGCTTCCTGTCGGCCCTCATTCGT 
For insertion of Tn3 E-helix ‘arm’ into 
Sin 
SEH9-T 20 bp GATCCTGATCAGCGGTACCG 
linker sequence to attach TALE DNA 
Binding domain to resolvase 
SEH9-B 20 bp CCGGCGGTACCGCTGATCAG 
linker sequence to attach TALE DNA 
Binding domain to resolvase 
SEH10a-T 61 bp 
CTAGTAAACAGTGGTCGGGAGCCCGGGCACTTGAGGCGCTGCTGA
CTGTGGCGGGTGAGCT 
linker sequence to attach TALE DNA 
Binding domain to resolvase 
SEH10a-B 43 bp AGTCAGCAGCGCCTCAAGTGCCCGGGCTCCCGACCACTGTTTA 
linker sequence to attach TALE DNA 
Binding domain to resolvase 
SEH10b-T 47 bp 
CCGCGGGCCTCCGCTGCAGCTCGACACCGGGCAGCTTTTAAAGATC
G 
linker sequence to attach TALE DNA 
Binding domain to resolvase 
SEH10b-B 61 bp 
CGATCTTTAAAAGCTGCCCGGTGTCGAGCTGCAGCGGAGGCCCGC
GGAGCTCACCCGCCAC 
linker sequence to attach TALE DNA 
Binding domain to resolvase 
SEH11-T 16 bp CTAGTTCCGCGGGTTC 
To introduce termination codon into 
TALER construct 
SEH11-B 16 bp AATTGAACCCGCGGAA 
To introduce termination codon into 
TALER construct 
SEH13-T 29 bp CTAGTGCTAGCAGAAGATCTTGATCAGCG 
linker sequence between TALE and 
resolvase, introducing restriction sites 
SEH13-B 29 bp GTACCGCTGATCAAGATCTTCTGCTAGCA 
linker sequence between TALE and 
resolvase, introducing restriction sites 
SEH14-T 13 bp CTAGTCACGAGGC 
linker sequence between TALE and 
resolvase 
SEH14-B 13 bp AATTGCCTCGTGA 
linker sequence between TALE and 
resolvase 
Table 2.4: Oligonucleotides used in this research (continued)       
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
SEH12*22-T 60 bp 
CAGATGTGGAAACGGAAGAAGCAAATATTATAAATTATAGCTCTTCCGTTT
CCACATCTG 
To introduce TALER  T-22  Site I 
SEH12*22-B 68 bp 
AATTCAGATGTGGAAACGGAAGAGCTATAATTTATAATATTTGCTTCTTCC
GTTTCCACATCTGAGCT 
To introduce TALER  T-22  Site I 
SEH15*18-T 56 bp 
CAGATGTGGAAACGGAAGACAAATATTATAAATTATATCTTCCGTTTCCAC
ATCTG 
To introduce TALER  T-18  Site I 
SEH15*18-B 64 bp 
AATTCAGATGTGGAAACGGAAGATATAATTTATAATATTTGTCTTCCGTTT
CCACATCTGAGCT 
To introduce TALER  T-18  Site I 
SEH16*20-T 58 bp 
CAGATGTGGAAACGGAAGAGCAAATATTATAAATTATAGTCTTCCGTTTCC
ACATCTG 
To introduce TALER  T-20  Site I 
SEH16*20-B 66 bp 
AATTCAGATGTGGAAACGGAAGACTATAATTTATAATATTTGCTCTTCCGT
TTCCACATCTGAGCT 
To introduce TALER  T-20  Site I 
SEH17*24-T 62 bp 
CAGATGTGGAAACGGAAGACAGCAAATATTATAAATTATAGCGTCTTCCG
TTTCCACATCTG 
To introduce TALER  T-24  Site I 
SEH17*24-B 70 bp 
AATTCAGATGTGGAAACGGAAGACGCTATAATTTATAATATTTGCTGTCTT
CCGTTTCCACATCTGAGCT 
To introduce TALER  T-24  Site I 
SEH18*26-T 64 bp 
CAGATGTGGAAACGGAAGAACAGCAAATATTATAAATTATAGCGAT
CTTCCGTTTCCACATCTG 
To introduce TALER  T-26  Site I 
SEH18*26-B 72 bp 
AATTCAGATGTGGAAACGGAAGATCGCTATAATTTATAATATTTGCT
GTTCTTCCGTTTCCACATCTGAGCT 
To introduce TALER  T-26  Site I 
SEH19*28-T 66 bp 
CAGATGTGGAAACGGAAGAGACAGCAAATATTATAAATTATAGCGA
GTCTTCCGTTTCCACATCTG 
To introduce TALER  T-28  Site I 
SEH19*28-B 74 bp 
AATTCAGATGTGGAAACGGAAGACTCGCTATAATTTATAATATTTGC
TGTCTCTTCCGTTTCCACATCTGAGCT 
To introduce TALER  T-28  Site I 
SEH25a-T 111 bp 
AATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTTAACGAATGACC
ATCTGGTGGCGTTGGCATGTCTTGGTGGACGACCCGCGCTCGATG
CAGTCAAAAAGGGTCTGCCTC 
To introduce Histidine (H6) Tag to 
TALER construct 
SEH25a-B 87 bp 
GCATCGAGCGCGGGTCGTCCACCAAGACATGCCAACGCCACCAG
ATGGTCATTCGTTAACGCAGCCAACGCGGGATCGGGCCTGGAC 
To introduce Histidine (H6) Tag to 
TALER construct 
Table 2.4: Oligonucleotides used in this research (continued)       
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
SEH25b-T 90 bp 
ATGCTCCCGCATTGATCAAAAGAACCAACCGGCGG 
ATTCCCGAGAGAACTTCCCATCGAGTCGCGCATCA 
CCATCACCATCACTGATCAG 
To introduce Histidine (H6) Tag to 
TALER construct 
SEH25b-B 114 bp 
GATCCTGATCAGTGATGGTGATGGTGATGCGCGACTCGATGGGA
AGTTCTCTCGGGAATCCGCCGGTTGGTTCTTTTGATCAATGCGGG
AGCATGAGGCAGACCCTTTTTGACT 
To introduce Histidine (H6) Tag to 
TALER construct 
SEH27-T 9 bp CTAGTATGT To make TALER 48 truncation 
SEH27-B 10 bp CCGGGACATA To make TALER 48 truncation 
SEH28-T 25 bp CTAGTCTTCTTGATTCGATGCCCGC To make TALER 84 truncation 
SEH28-B 19 bp GGGCATCGAATCAAGAAGA To make TALER 84 truncation 
SEH29-T 11 bp CTAGTCCCACC To make TALER 119 truncation 
SEH29-B 11 bp GTACGGTGGGA To make TALER 119 truncation 
SEH30-T 18 bp CTAGTCCGGCAGCACAGG To make TALER 149 truncation 
SEH30-B 18 bp TCGACCTGCGCTGCCGGA To make TALER 149 truncation 
SEH31-T 30 bp TATGAAAGACCTAATCATTCGAATATTAGC To make Sin Q115R 109 tadpole 
SEH31-B 32bp CATGGCTAATATTCGAATGATTAGGTCTTTCA To make Sin Q115R 109 tadpole 
Table 2.4: Oligonucleotides used in this research (continued)       
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
SEH32-T 30 bp TATGGCAGACCTAATCATTCAAATATTAGC 
To make Sin WT 109 K110A E-
helix mutant tadpole 
SEH32-B 32 bp CATGGCTAATATTTGAATGATTAGGTCTGCCA 
To make Sin WT 109 K110A E-
helix mutant tadpole 
SEH33-T 30 bp TATGAAAGACGCAATCATTCAAATATTAGC 
To make Sin WT 109 L112A E-
helix mutant tadpole 
SEH33-B 32 bp CATGGCTAATATTTGAATGATTGCGTCTTTCA 
To make Sin WT 109 L112A E-
helix mutant tadpole 
SEH34-T 30 bp TATGAAAGACCTAATCGCTCAAATATTAGC 
To make Sin WT 109 I114A E-
helix mutant tadpole 
SEH34-B 32 bp CATGGCTAATATTTGAGCGATTAGGTCTTTCA 
To make Sin WT 109 I114A E-
helix mutant tadpole 
SEH35-T 30 bp TATGAAAGACCTAATCATTCAAGCATTAGC 
To make Sin WT 109 I116A E-
helix mutant tadpole 
SEH35-B 32 bp CATGGCTAATGCTTGAATGATTAGGTCTTTCA 
To make Sin WT 109 I116A E-
helix mutant tadpole 
SEH36-T 66 bp 
TATGAAAGACCTAATCATTCAAATATTAGCCGCGGTTTCGGAACAA
GAACGAAATGAAAGTAAACG 
To make Sin WT 109 M119A E-
helix mutant tadpole 
SEH36-B 68 bp 
TCGACGTTTACTTTCATTTCGTTCTTGTTCCGAAACCGCGGCTAAT
ATTTGAATGATTAGGTCTTTCA 
To make Sin WT 109 M119A E-
helix mutant tadpole 
SEH37-T 66 bp 
TATGAAAGACCTAATCATTCAAATATTAGCCATGGTTGCGGAACAA
GAACGAAATGAAAGTAAACG 
To make Sin WT 109 S121A E-
helix mutant tadpole 
SEH37-B 68 bp 
TCGACGTTTACTTTCATTTCGTTCTTGTTCCGCAACCATGGCTAAT
ATTTGAATGATTAGGTCTTTCA 
To make Sin WT 109 S121A E-
helix mutant tadpole 
Table 2.4: Oligonucleotides used in this research (continued)       
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
SEH40-T 52 bp 
GTAACCCATTACTAGATAAATTTATGGCAGACCTAATCATTCGAAT
ATTAGC 
To make Full-length Sin Q115R 
K110A E-helix mutant 
SEH40-B 51 bp 
CATGGCTAATATTCGAATGATTAGGTCTGCCATAAATTTATCTAGT
AATGG 
To make Full-length Sin Q115R 
K110A E-helix mutant 
SEH41-T 52 bp 
GTAACCCATTACTAGATAAATTTATGAAAGACGCAATCATTCGAAT
ATTAGC 
To make Full-length Sin Q115R 
L112A E-helix mutant 
SEH41-B 51 bp 
CATGGCTAATATTCGAATGATTGCGTCTTTCATAAATTTATCTAGTA
ATGG 
To make Full-length Sin Q115R 
L112A E-helix mutant 
SEH42-T 52 bp 
GTAACCCATTACTAGATAAATTTATGAAAGACCTAATCGCTCGAAT
ATTAGC 
To make Full-length Sin Q115R 
I114A E-helix mutant 
SEH42-B 51 bp 
CATGGCTAATATTCGAGCGATTAGGTCTTTCATAAATTTATCTAGT
AATGG 
To make Full-length Sin Q115R 
I114A E-helix mutant 
SEH43-T 52 bp 
GTAACCCATTACTAGATAAATTTATGAAAGACCTAATCATTCGAGC
ATTAGC 
To make Full-length Sin Q115R 
I116A E-helix mutant 
SEH43-B 51 bp 
CATGGCTAATGCTCGAATGATTAGGTCTTTCATAAATTTATCTAGT
AATGG 
To make Full-length Sin Q115R 
I116A E-helix mutant 
SEH44-T 88 bp 
GTAACCCATTACTAGATAAATTTATGAAAGACCTAATCATTCGAATA
TTAGCCGCGGTTTCGGAACAAGAACGAAATGAAAGTAAACG 
To make Full-length Sin Q115R 
M119A E-helix mutant 
SEH44-B 87 bp 
TCGACGTTTACTTTCATTTCGTTCTTGTTCCGAAACCGCGGCTAAT
ATTCGAATGATTAGGTCTTTCATAAATTTATCTAGTAATGG 
To make Full-length Sin Q115R 
M119A E-helix mutant 
SEH45-T 36 pb CATGGTTGCGGAACAAGAACGAAATGAAAGTAAACG 
To make Full-length Sin Q115R 
S121A E-helix mutant 
SEH45-B 36 bp TCGACGTTTACTTTCATTTCGTTCTTGTTCCGCAAC 
To make Full-length Sin Q115R 
S121A E-helix mutant 
Table 2.4: Oligonucleotides used in this research (continued)       
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Oligo ID: 
Size 
(bp) 
Sequence (5’-3’) Purpose 
SEH48-T 75 bp 
CATGCCGGGAAGATGTGGAAACGGAAGAAGCAAATATTATAAATT
ATAGCTCTTCCGTTTCCACATCTAAGAATT 
T-22 TALER Site to be 5’ end 
labelled for In vitro binding assays 
SEH48-B 76 bp 
CTAGAATTCTTAGATGTGGAAACGGAAGAGCTATAATTTATAATAT
TTGCTTCTTCCGTTTCCACATCTCTCCCGG 
T-22 TALER Site to be 5’ end 
labelled for In vitro binding assays 
SEH49-T 58 bp 
CATGCCGGGAGCTCACTAGTATGTATGATTAGGGTATACCCTAAT
CATACAAAGAATT 
58bp RSinR Site I to be 5’ end 
labelled for In vitro binding assays 
SEH49-B 58 bp 
CTAGAATTCTTTGTATGATTAGGGTATACCCTAATCATACATACTA
GTGAGCTCCCGG 
58bp RSinR Site I to be 5’ end 
labelled for In vitro binding assays 
SEH50-T 58 bp 
CATGCCGGGAGCTCACTAGTATGTATGATTATATTATAATATAATC
ATACAAAGAATT 
RTn3R Site I to be 5’ end labelled 
for In vitro binding assays 
SEH50-B 58 bp 
CTAGAATTCTTTGTATGATTATATTATAATATAATCATACATACTAGT
GAGCTCCCGG 
RTn3R Site I to be 5’ end labelled 
for In vitro binding assays 
SEH51-T 58 bp 
CATGCCGGGAGCTCACTAGTAAACGGCGGCAAATCGTACCCTAAT
CATACAAAGAATT 
R Site I to be 5’ end labelled for In 
vitro binding assays 
SEH51-B 58 bp 
CTAGAATTCTTTGTATGATTAGGGTACGATTTGCCGCCGTTTACTA
GTGAGCTCCCGG 
R Site I to be 5’ end labelled for In 
vitro binding assays 
SEH52-T 45 bp CATGCCGGGATGTATGATTAGGGTATACCCTAATCATACAGAATT 
45bp RSinR Site I to be 5’ end 
labelled for In vitro binding assays 
SEH52-B 45 bp CTAGAATTCTGTATGATTAGGGTATACCCTAATCATACATCCCGG 
45bp RSinR Site I to be 5’ end 
labelled for In vitro binding assays 
SEH53-T 77 bp 
CATGCCGCTAGCCGCCTAGGCTATCAGTATGTATGATTAGGGTAT
ACCCTAATCATACAAAGAGCGTCGCTACTATT 
77bp RSinR Site I to be 5’ end 
labelled for In vitro binding assays 
SEH53-B 77 bp 
CTAGAATAGTAGCGACGCTCTTTGTATGATTAGGGTATACCCTAAT
CATACATACTGATAGCCTAGGCGGCTAGCGG 
77bp RSinR Site I to be 5’ end 
labelled for In vitro binding assays 
Table 2.4: Oligonucleotides used in this research (continued)       
  
 
 
 
 
 
Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pCO1 ApR 2543 pMTL23 with Tn3 Site I cloned in between EcoRI and SacI C.Muir/M.Stark 
pDB34 KmR 8371 
In vivo recombination substrate, containing two copies of Tn3 res site in 
direct repeat, flanking a GalK gene 
Arnold et al. 
pMS140 ApR 5469 
pAT5 derivative encoding the Tn3 resolvase ORF, with low level 
expression suitable for in vivo recombination assays 
M.Stark 
pMS183 Km
R 4863 
In vivo recombination substrate precursor plasmid, allows cloning of 
recombination between BglII/BsrGI and NcoI/XbaI flanking galK indicator 
M.Prorocic 
pMTL23 ApR 2505 Cloning vector 
Chambers et 
al. 1988 
pSA1101 KmR 6692 Wild type Tn3 resolvase expression plasmid with inducible T7 promoter 
Arnold et al. 
1999 
pSA1121 KmR 6711 
Wild type Tn3 resolvase expression plasmid with inducible T7 promoter 
and C-terminal Histidine tag 
Rowland et al. 
2005 
pSA1171 KmR 6762 
Q115R Sin resolvase expression plasmid with inducible T7 promoter and 
C-terminal Histidine tag 
S.Rowland 
pSA1195 KmR 6438 
109 [V138A] Sin resolvase expression plasmid with inducible T7 
promoter and C-terminal Histidine tag 
S.Rowland 
pSA1196 KmR 6393 
124 [V138A] Sin resolvase expression plasmid with inducible T7 
promoter and C-terminal Histidine tag 
S.Rowland 
pSA9944 ApR 5535 Low level expression plasmid, encoding wild type Sin resolvase 
Mouw et al. 
2008 
Table 2.5: Plasmids constructed for this research and their precursors. Plasmid names are highlighted according to plasmid 
type: Yellow = pMTL23-based single site recombination plasmids, light green = pMS140 based low level resolvase 
expression plasmids, dark green = pSA1101-derived resolvase overexpression plasmids, blue = 2-site in vitro recombination 
substrate plasmid, red = 2-site in vivo recombination substrate plasmid, purple = high copy number 2-site in vitro substrate.       
 Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pSA9994 ApR 5539 Low level expression plasmid encoding Sin resolvase Q115R mutant S.Rowland 
pSE1005 ApR 2544 
pMTL23 with oligo for symmetrised Sin Site I (RSinR) cloned in between 
AlwNI-SacI 
Section2.7.iv 
pSE1006 ApR 2544 
pMTL23 with oligo for symmetrised Tn3 Site I (RTn3R) cloned in between 
AlwNI-SacI 
Section2.7.iv 
pSE1008 ApR 2544 pMTL23 with oligo for Sin Half-Site I (R) cloned in between AlwNI-SacI Section2.7.iv 
pSE1012 KmR 4950 
In vivo recombination substrate, containing two copies of symmetrised Sin 
Site I in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1013 KmR 4950 
In vivo recombination substrate, containing two copies of symmetrised 
Tn3 Site I in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1014 KmR 4950 
In vivo recombination substrate, containing two copies of Sin Half-Site I in 
direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1020 ApR 2563 pMTL23 with oligo for T-22 NM Site I cloned in between EcoRI-SacI Section2.7.iv 
pSE1021 KmR 4984 
In vivo recombination substrate, containing two copies of T-22 NM Site I 
in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1022 ApR 2559 pMTL23 with oligo for T-18 NM Site I cloned in between EcoRI-SacI Section2.7.iv 
pSE1023 ApR 2561 pMTL23 with oligo for T-20 NM Site I cloned in between EcoRI-SacI Section2.7.iv 
 
 
 
 
 
Table 2.5 (continued).  
 Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pSE1024 ApR 2565 pMTL23 with oligo for T-24 NM Site I cloned in between EcoRI-SacI Section2.7.iv 
pSE1025 ApR 2567 pMTL23 with oligo for T-26 NM Site I cloned in between EcoRI-SacI Section2.7.iv 
pSE1026 ApR 2569 pMTL23 with oligo for T-28 NM Site I cloned in between EcoRI-SacI Section2.7.iv 
pSE1027 KmR 4976 
In vivo recombination substrate, containing two copies of T-18 NM Site I 
in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1028 KmR 4980 
In vivo recombination substrate, containing two copies of T-20 NM Site I 
in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1029 KmR 4988 
In vivo recombination substrate, containing two copies of T-24 NM Site I 
in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1030 KmR 4992 
In vivo recombination substrate, containing two copies of T-26 NM Site I 
in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1031 KmR 4996 
In vivo recombination substrate, containing two copies of T-28 NM Site I 
in direct repeat, flanking a GalK gene 
Section 2.7.v 
pSE1032 KmR 4943 
pSB424 based in vivo binding substrate with one copy of T-24 NM site I 
containing GalK promoter 
Section2.7.iv 
pSE1033 KmR 4945 
pSB424 based in vivo binding substrate with one copy of T-26 NM site I 
containing GalK promoter 
Section2.7.iv 
pSE1034 KmR 4947 
pSB424 based in vivo binding substrate with one copy of T-28 NM site I 
containing GalK promoter 
Section2.7.iv 
 
 
 
 
Table 2.5 (continued).  
 Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pUC4K KanR/AmpR 3914 
High copy number cloning vector used for construction of in vitro 
substrates 
Amersham 
bioscience 
pSE1041 KanR/AmpR 3955 High copy number in vitro substrate with two copies of T-20 site I Section 4.4 
pSE1042 KanR/AmpR 3959 High copy number in vitro substrate with two copies of T-22 site I Section 4.4 
pSE1043 KanR/AmpR 3963 High copy number in vitro substrate with two copies of T-24 site I Section 4.4 
pSE1044 KanR/AmpR 3967 High copy number in vitro substrate with two copies of T-26 site I Section 4.4 
pSE1045 KanR/AmpR 3971 High copy number in vitro substrate with two copies of T-28 site I Section 4.4 
pSE2001 KmR 6462 
Truncated (M101) Sin resolvase expression plasmid with inducible T7 
promoter 
Section 3.2.ii 
pSE2003 KmR 6438 
Truncated (M109) Sin resolvase expression plasmid with inducible T7 
promoter 
Section 3.2.ii 
pSE2004 KmR 6393 
Truncated (M124) Sin resolvase expression plasmid with inducible T7 
promoter 
Section 3.2.ii 
pSE2005 KmR 6405 Wild Type Tn3 resolvase expression plasmid with inducible T7 promoter Section 3.2.ii 
pSE2028 ApR 5636 
Low copy number expression plasmid, pMS140 with pAMC1-4 (Tn3 
ZFR) cloned in between EcoRI and Asp718 
Section 2.7.iii 
 
 
 
 
Table 2.5 (continued).  
  
 
 
 
Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pSE2029 ApR 5382 
Low copy number expression plasmid, pSE2028 with oligo to introduce 
restriction sites for linker insertion 
Section 2.7.iii 
pSE2031 ApR 7452 
Low copy number expression plasmid with TAL 1297 truncated at position 
222 
Section 2.7.iii 
pSE2033 KmR 8675 TALER TAL222 expression plasmid with inducible T7 promoter Section 2.7.i 
pSE2034 ApR 7640 
Low copy number TALER TAL-222 expression plasmid with a 6aa GS 
linker 
Section 2.7.iii 
pSE2035 ApR 7644 
Low copy number TALER TAL-222 expression plasmid with a 9aa GS 
linker 
Section 2.7.iii 
pSE2036 ApR 7648 
Low copy number TALER TAL-222 expression plasmid with a 12aa GS 
linker 
Section 2.7.iii 
pSE2037 ApR 7652 
Low copy number TALER TAL-222 expression plasmid with a 7aa GS 
linker 
Section 2.7.iii 
pSE2040 ApR 7656 
Low copy number TALER 154 expression plasmid, made from pSE2030 
with oligo SEH20 cloned in between SpeI-Bsu36I 
Section 2.7.iii 
pSE2041 ApR 7662 TALER 154 low copy number expression plasmid with a 6aa GS linker Section 2.7.iii 
pSE2050 KmR 8879 TALER 154 expression plasmid with inducible T7 promoter Section 2.7.i 
pSE2051 KmR 8885 
TALER 154 expression plasmid with a 6aa GS linker and an inducible 
T7 promoter 
Section 2.7.i 
pSE2060 KmR 9354 
Tn3-TALER with 6aa linker and 
GeneArt TAL 1-(+63)H6 with inducible T7 promoter 
Section 2.7.i 
Table 2.5 (continued).  
  
 
 
Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pSE2065 ApR 8131 
Low copy number plasmid expressing Tn3-TALER with 6aa linker and 
GeneArt TAL 1-(+63)H6 
Section 2.7.iii 
pSE2080 KmR 9213 
NM resolvase 1-144 with 6aa linker and 
GeneArt TAL 48-(+63)H6 with T7 inducible promoter 
Section 2.7.i 
pSE2085 ApR 7990 
Low copy number  plasmid expressing NM resolvase 1-144 with 6aa 
linker and GeneArt TAL 48-(+63)H6 
Section 2.7.iii 
pSE2090 KmR 9105 
NM resolvase 1-144 with 6aa linker and 
GeneArt TAL 84-(+63)H6 with T7 inducible promoter 
Section 2.7.i 
pSE2095 ApR 7882 
Low copy number plasmid expressing NM resolvase 1-144 with 6aa linker 
and GeneArt TAL 84-(+63)H6 
Section 2.7.iii 
pSE2100 KmR 9003 
NM resolvase 1-144 with 6aa linker and 
GeneArt TAL 119-(+63)H6 with T7 inducible promoter 
Section 2.7.i 
pSE2105 ApR 7777 
Low copy number plasmid expressing NM resolvase 1-144 with 6aa linker 
and GeneArt TAL 119-(+63)H6 
Section 2.7.iii 
pSE2110 KmR 8913 
NM resolvase 1-144 with 6aa linker and 
GeneArt TAL 149-(+63)H6 with T7 inducible promoter 
Section 2.7.i 
pSE2115 ApR 7687 
Low copy number plasmid expressing NM resolvase 1-144 with 6aa linker 
and GeneArt TAL 149-(+63)H6 
Section 2.7.iii 
pSE2300 KmR 6438 
Truncated (M109) His-6 tagged Q115R Sin resolvase expression 
plasmidwith inducible T7 promoter 
Section3.3.i 
pSE2301 KmR 6438 
Truncated (M109) His-6 tagged Sin resolvase expression plasmid with 
K110A E-helix mutation and inducible T7 promoter 
Section3.3.i 
Table 2.5 (continued).  
 Plasmid 
Antibiotic 
Marker 
Size 
(bp) 
Description Source 
pSE2302 KmR 6438 
Truncated (M109) His-6 tagged Sin resolvase expression plasmid with 
L112A E-helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2303 KmR 6438 
Truncated (M109) His-6 tagged Sin resolvase expression plasmid with 
I114A E-helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2304 KmR 6438 
Truncated (M109) His-6 tagged Sin resolvase expression plasmid with 
I116A E-helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2305 KmR 6438 
Truncated (M109) His-6 tagged Sin resolvase expression plasmid with 
M119A E-helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2306 KmR 6438 
Truncated (M109) His-6 tagged Sin resolvase expression plasmid with 
S121A E-helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2315 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with inducible T7 
promoter 
Section3.3.i 
pSE2316 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with K110A E-
helix mutation and inducible T7 promoter  inducible T7 promoter 
Section3.3.i 
pSE2317 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with L112A E-
helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2318 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with I114A E-helix 
mutation and inducible T7 promoter 
Section3.3.i 
pSE2319 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with I116A E-helix 
mutation and inducible T7 promoter 
Section3.3.i 
pSE2320 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with M119A E-
helix mutation and inducible T7 promoter 
Section3.3.i 
pSE2321 KmR 6762 
His-6 tagged Q115R Sin resolvase expression plasmid with S121A E-
helix mutation and inducible T7 promoter 
Section3.3.i 
 
 
Table 2.5 (Continued).  
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Figure 2.1: High level expression plasmids constructed based on pSA1101. 
High-level expression plasmids have a ColEI origin of replication, a kanamycin 
resistance marker and an IPTG-inducible T7 promoter. A resolvase open reading 
frame (green) is cloned in between NdeI and Asp718 in the pSA1101 backbone.  
  
  pSA1101 
  (6407 bp)   pSE2031 
  (7452 bp) 
  pSE2033 
  (8675 bp) 
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2.7.ii Low level resolvase expression plasmids 
 
All low level expression plasmids were constructed based on a pMS140 
backbone (Burke et al 2004). pMS140 has a ColEI origin of replication, 
contains an ampicillin resistance marker and expresses a cassetted version 
of wild-type Tn3 resolvase, cloned between the restriction sites NdeI and 
Asp718. Expression of resolvase in pMS140-derived plasmids is driven by an 
unidentified promoter situated within 400 bp upstream of the NdeI site. The 
low level of expression is suitable for in vivo recombination assays. pMS140 
and all of its derivatives contain a unique EagI restriction site within the 
resolvase reading frame after the conserved GR motif (amino acid residues 
G141 and R142). This allows the swapping of the C-terminus of Tn3 
resolvase with DNA-binding domains from other proteins, such as Sin in 
Tn3/Sin hybrid proteins or TALE domains in TALER hybrids.   
 
 
2.7.iii In vitro recombination substrate plasmids 
 
pMTL23 is the precursor to the in vivo and in vitro two-site plasmids. pMTL23 
is a high copy number cloning vector containing an ampicillin resistance 
marker and a deregulated ColEI origin of replication (Chambers et al. 1988). It 
contains a large polylinker, with many useful restriction sites. The res sites 
utilised in this study were cloned into the pMTL23 vector as oligonucleotides 
(MB67/71, MB68/72 and MB70/74; see table 2.4) between the restriction sites 
AlwNI-SacI The res site can be excised from this plasmid between the 
restriction sites XbaI-NcoI and BamHI-Asp718 for construction of 2-site 
substrates for in vivo assays (section 2.7.iv).  
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2.7.iv In vivo recombination substrate plasmids 
 
All substrate plasmids used for in vivo assays in this study are based on a 
pMS183 backbone. pMS183 expresses a kanamycin resistance marker 
and has a pSC101 replication origin. In vivo recombination substrates were 
constructed by a four-piece ligation, with BglII-NcoI and BsrGI-XbaI from 
pMS183 and XbaI-NcoI and BamHI-Asp718 from a pMTL23-based single 
site plasmid (Figure 2.2). This cloning is made possible by the compatibility of 
the sticky ends made by the enzymes BsrGI and Asp718, and BglII and 
BamHI respectively. 
 
2.8 Making E.coli cells competent 
 
Competent E.coli cells for DNA transformation were prepared routinely by 
chemical treatment of log phase cultures (section 2.8.i). When higher 
transformation efficiency was required, cells were prepared by an alternate 
method making them suitable for electroporation (section 2.8.ii).   
 
 
2.8.i Chemically competent cells 
 
Chemically competent cells were prepared by inoculating 10 ml of L-broth 
with 200 l of an overnight E.coli culture and growing at 37C with shaking at 
250 rpm (New Brunswick Scientific Excella E24 Incubator Shaker) to an 
OD600 of 0.4-0.5 (mid-log phase). The culture was divided into four aliquots of 
1.2 ml and chilled on ice. Cells were harvested by centrifugation in a pre-
cooled rotor at 4C for 1 minute at 9300 x g, after which the supernatant was 
removed. The cell pellet was re-suspended in 1.2 ml ice-cold 50 mM CaCl2 
and the centrifugation step was repeated. Following the second centrifugation 
step, the supernatant was removed and the cell pellet was re-suspended in 
200 l ice-cold 50 mM CaCl2. Cells prepared by this method were stored on 
ice until use, and remained competent for up to 48 hours. 
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Figure 2.2: In vivo 2-site substrate construction.  
res sites from a pMTL23-based plasmid were cloned into the galK expressing 
plasmid pMS183 on BamHI-Asp718 and XbaI-NcoI fragments. This cloning was 
made possible by the compatibility of the enzymes BsrGI and Asp718 and of BglII 
and BamHI. 
 
  
pSE1012 
(4950bp) 
pMS183 
(4863bp) 
pSE1005 
(2544bp) 
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2.8.ii Electro-competent cells 
 
To prepare electro-competent cells 400 ml of L-broth was inoculated with 2ml 
of an overnight culture, cells were then grown at 37C with shaking at 250 
rpm (New Brunswick Scientific Excella E24 Incubator Shaker) to an OD600 of 
0.4-0.5 (mid-log phase). The culture was then divided into two 200 ml aliquots 
and chilled on ice. Cells were harvested by centrifugation in a pre-cooled rotor 
(Beckman Coulter JA-14) at 4C for 15 mins at 4000 x g. The supernatant 
was removed, the cell pellet was re-suspended in 400 ml ice-cold 10% 
glycerol and centrifugation was repeated. The resulting cell pellet was re-
suspended in 200 ml ice cold 10% glycerol and the centrifugation repeated. 
Following this, the cell pellet was re-suspended in 20 ml ice-cold 10% 
glycerol, and the suspension was transferred to a 30 ml polypropylene tube 
and centrifuged (Beckman coulter JA-20) at 4C for 15 mins at 4000 rpm. 
Finally, the pellet was re-suspended in 2 ml ice-cold 10% glycerol. The cells 
were divided into 20 l aliquots, flash-frozen in liquid nitrogen and stored at 
70 C. Cells thus prepared can be stored for up to six months.  
 
 
2.9 Transformation of competent cells 
 
2.9.i Transformation of chemically competent E.coli cells 
 
100 l of chemically competent cells was mixed with 0.01-0.1 g of plasmid 
DNA and the mixture was incubated on ice for 20 mins. The cells were then 
heat-shocked at 42C in a water bath for 2 mins, followed by incubation on ice 
for 5 mins. 1 ml of L-broth was added and the cells were incubated at 37C 
for 60-90 mins to allow expression of the plasmid. Aliquots of this liquid 
culture were spread on selective L-agar plates (section 2.2) and incubated at 
37C overnight.  
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2.9.ii Transformation of electro-competent cells 
 
0.01 g of DNA was added to a 20 l aliquot of cells, and transferred to an 
ice-cold electroporation cuvette. An electrical pulse was delivered by a Biorad 
Micropulser and 1 ml L-broth was immediately added. The culture was then 
transferred to a 2 ml Nunc tube and incubated at 37C with shaking at 250 
rpm (New Brunswick Scientific Excella E24 Incubator Shaker) for 60 mins. 
After this recovery stage, aliquots of the culture were spread on selective agar 
plates and incubated overnight at 37C.  
 
 
2.10 Plasmid DNA preparation 
 
Plasmid DNA for use in most experiments was prepared on a small scale. For 
in vitro experiments, where larger quantities of DNA were required, a larger 
scale preparation method was used (Section 2.10.ii). Small scale DNA 
preparation (section 2.10.i) was carried out using a Qiagen mini-prep kit, 
which uses a silica-gel membrane system to bind DNA. The larger scale 
preparation (section 2.10.ii) used a Qiagen midi-prep kit, which uses a silica-
gel beaded column system to bind the DNA. 
 
 
2.10.i Small Scale DNA preparation 
 
Plasmid mini-preps were carried out using a Qiagen plasmid mini-prep kit. 
Each mini-prep was carried out using a pellet from 4.5 ml of culture. Other 
steps were carried out according to the manufacturer’s instructions. 
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2.10.ii Medium Scale DNA preparation 
 
Plasmid midi-preps were carried out using a Qiagen midi-prep kit and a pellet 
from 25 ml of cell culture. The DNA preparation was carried out according to 
the manufacturer’s instructions. 
 
 
2.11 Ethanol precipitation of DNA 
 
DNA obtained by the Qiagen DNA preparation method can be ethanol- 
precipitated to further purify it.  Ammonium acetate solution was added to a 
final concentration of 0.5 M, and 2.2x sample volume of 100% ethanol was 
then added. The mix was then incubated on ice for 15-30 minutes, followed 
by centrifugation at 4C for 30 minutes at 9300 x g. The supernatant was 
removed and the pellet was washed with 100 l 80% ethanol. Centrifugation 
was repeated at 4C, 9300 x g for 20 minutes, the supernatant was removed 
and the resulting pellet was re-suspended in 20 l TE buffer (10 mM Tris/HCl 
(pH8), 0.1 mM EDTA).   
 
 
2.12 Digestion of DNA by restriction endonucleases 
 
Restriction endonucleases were used to digest the DNA, using 2-10 units of 
enzyme per microgram of DNA and utilising the supplier’s recommended 
buffer. Digests were typically incubated at 37C for 1 hour (unless otherwise 
stated in the manufacturer’s instructions). SDS loading buffer (1% SDS, 50% 
glycerol, 0.01% bromophenol blue) was added at a 1:5 ratio following 
incubation to stop the reaction.  
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2.13 Gel electrophoresis 
 
DNA fragments were separated according to size using either agarose 
(section 2.13.i) or polyacrylamide (section 2.13.ii) gel electrophoresis for large 
supercoiled/linear fragments >200 bp in size or small (<200 bp) fragments 
respectively. Oligonucleotide purification and protein separation were also 
carried out using polyacrylamide gels (see sections 2.19 and 2.23). 
 
 
2.13.i Agarose gel electrophoresis 
 
Agarose gel electrophoresis was routinely used to separate restriction digest 
fragments between 200 bp and 4000 bp in size. Agarose gels of 1-1.2% w/v 
were made by dissolving agarose (Biorad ultrapure) in 100 ml TAE buffer (40 
mM Tris/ acetate, 1 mM EDTA, pH 8.5) by heating in a microwave oven. 
The agarose was then cooled and poured onto a gel plate and fitted with a 
well-forming comb. Once set, the comb was removed, samples were added to 
the wells and the gels were run at room temperature for 60-90 minutes at 150 
V in TAE gel running buffer. The gel was then stained and visualised (section 
2.16).  
 
 
2.13.ii Polyacrylamide gel electrophoresis 
 
Polyacrylamide gel electrophoresis was used to separate DNA fragments 
<200 bp in size. Gels for separation of double stranded DNA were typically 
12% acrylamide and were prepared by making 30 ml of gel solution (12%  
acrylamide/bis acrylamide (19:1), 3 ml 10x TBE buffer (89 mM Tris base, 2 
mM EDTA, 89 mM boric acid), 15 ml H2O, 75 l 20% ammonium persulphate 
(APS) and 10 l TEMED (N,N,N’,N’-tetramethylethylenediamine).  For single 
stranded oligonucleotide purification gels, the acrylamide was typically as 
above with the addition of 7 M urea.  
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For protein separation (section 2.23), gels were routinely made at 15% (15% 
acrylamide/bisacrylamide (37.5:1), 375 mM Tris/HCl (pH 8.8), 0.1% SDS, 
0.1% APS, 0.2% TEMED). 
 
For binding assay gels (section 2.29), gels were typically made at 5% 
acrylamide, with the addition of glycerol and were prepared by making 30 ml 
of gel solution (5%  acrylamide/bis acrylamide (19:1), 3 ml 10x TBE buffer (89 
mM Tris base, 2 mM EDTA, 89 mM boric acid), 3ml glycerol, 12ml H2O, 75 l 
20% ammonium persulphate (APS) and 10 l TEMED (N,N,N’,N’-
tetramethylethylenediamine).   
 
The gel mix was poured between sealed and clamped glass plates with 0.75 
mm spacers and a well-forming comb inserted. Polymerisation was allowed to 
continue for 1 hour. Following polymerisation, the clamps, comb and sealing 
were removed and the gel was inserted into a vertical electrophoresis kit. The 
gel was run at 220 V for 2.5-3 h at room temperature in 1x TBE running 
buffer. DNA bands separated by this method were visualised by ethidium 
bromide staining (section 2.16).  
 
 
2.14 DNA size marker ladder 
 
For estimation of DNA fragment size, a NEB 1kb or 1kb+ marker ladder was 
used as appropriate. 
 
 
2.15 Sample loading buffers 
 
Prior to loading of restriction digest samples onto an agarose gel, one volume 
of SDS loading buffer was added to 5 volumes of sample. For in vitro 
cleavage and resolution reactions, the same ratio of SDS-K loading buffer 
(1% SDS, 50% glycerol, 0.01% bromophenol blue, 1 mg/ml protease K) was 
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added to the sample, with the protease acting to digest the resolvase, 
allowing the bands to be clearly visualised.  
 
 
2.16 Visualisation of DNA by ethidium bromide staining 
 
DNA bands on both agarose and polyacrylamide gels were visualised by 
staining with a 0.6 g/ml ethidium bromide (EtBr) solution (15 mg/ml EtBr 
stock, added to 1x gel running buffer) for 30-60 minutes. Gels stained in this 
way were de-stained by soaking in de-ionised water for a further 30-60 
minutes to remove background ethidium bromide fluorescence. EtBr-stained 
bands were visualised on a long wavelength (365 nm) UV transilluminator for 
preparative gels where bands were to be extracted for DNA purification 
purposes or on a short wavelength (254 nm) UV transilluminator for 
visualisation and photographing of gels.    
 
 
2.17 DNA extraction from gels 
 
DNA was extracted from agarose gels by cutting out a gel slice, visualised by 
350 nm transillumination of an ethidium bromide-stained gel using a scalpel, 
and filtering the DNA through a 0.45 M Costar column by centrifugation for 1 
minute at 10,000 rpm 
 
 
2.18 Purification and annealing of oligonucleotides 
 
Oligonucleotides obtained from MWG Eurofins Operon were re-suspended in 
an appropriate volume of TE buffer (10 mM Tris/HCl, 0.1 mM EDTA) 
according to the provided oligonucleotide synthesis sheet, to give a final 
concentration of 100 M. 1 volume of loading buffer was added to 5 volumes 
of oligonucleotide. Typically 30l of 100 M oligonucleotide/loading buffer 
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was loaded onto a 12% urea/acrylamide gel (section 2.13) and run in TBE 
buffer at 20 W (450-500 V) for 3 hours. Gels were then stained using 
StainsAll (1-Ethyl-2-[3-(1-ethylnaphtho[1,2-d]thiazolin-2-ylidene)-2 
methylpropenyl] naphtho[1,2-d]thiazolium bromide) stain (Sigma Aldrich) and 
the DNA was excised in a gel slice using a scalpel.  Crush and soak followed 
by ethanol precipitation was then used for purification of the DNA (sections 
2.26 and 2.11). Purified single stranded oligonucleotides were then annealed 
by mixing the top and bottom strands in a 1:1 ratio with 100 mM NaCl and 1x 
TE buffer, heating to 9 C.  
 
 
2.19 Ligation of DNA fragments from restriction digests 
 
For cloning, DNA fragments were ligated in Invitrogen ligation buffer (50 mM 
Tris/HCl (pH 7.6), 10 mM MgCl2, 1 mM dithiothreitol (DTT), 5% w/v 
polyethylene glycol-8000) using 1 unit of T4 DNA ligase in a final volume of 
20 l. The ratio of vector to insert was typically 1:3. Ligation reactions were 
carried out at room temperature overnight and used to transform competent 
E.coli cells (section 2.8).  
 
 
2.20 Sequencing plasmid DNA 
 
Sequencing of DNA samples was carried out commercially by MWG Eurofins 
Genomics (Ebersberg, Germany). Plasmid DNA was prepared as 
recommended by MWG. For high copy number expression vectors, the MWG 
T7 sequencing primer was routinely used and for the pMTL23-type substrate 
vectors, the MWG M13-rev (-49) sequencing primer was typically used.  
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2.21 In vivo (MacConkey) recombination assay 
 
The MacConkey assay (Blake 1993) was used to screen for in vivo  
recombination activity. E.coli cells (DS941 strain, galk-) containing a low level 
resolvase expression plasmid (section 2.7.3) were made competent (section 
2.8), usually using the CaCl2 method and transformed (section 2.8.1) with 
~0.01 g in vivo recombination substrate plasmid, with a kanamycin 
resistance gene and two recombination sites in direct repeat flanking a galK 
gene. 
 
Following transformation, cells were plated out on MacConkey indicator agar 
plates (Difco), with 2% galactose added and incubated overnight at 37C. 
Plates were photographed (Canon EOS D30). A sample of cells was then 
scraped off the plates and grown overnight in L-broth. Plasmid DNA isolated 
from pelleted cells was then analysed by agarose gel electrophoresis 
following EtBr staining of the DNA. 
 
Recombination of the substrate plasmid by resolvase (resolution) produces 
two circular DNA molecules, one containing the origin of replication and 
kanamycin resistance gene and the other the galK gene. The latter, having no 
origin of replication, is not maintained in the cell and is lost in subsequent cell 
divisions. MacConkey agar has no carbon source (other than the added 
galactose) and contains a pH indicator (2-methyl-3-amino-6-
dimethylaminophenazine) which is yellow at pH >8.0 and red at pH <6.8. 
Successful resolution of the substrate plasmid forces the E.coli to metabolise 
amino acids in the agar as they are unable to metabolise galactose, resulting 
in an increase in pH and production of white colonies. Unresolved substrate 
with the galK gene, allows the E.coli to metabolise galactose, lowering the pH 
and producing red colonies (figure 2.3). 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
C
Kan 
res 
res Ori 
galK 
Resolvase 
Transform 
Resolvase 
Resolvase 
Resolvase 
Kan 
res 
res Ori 
galK 
Kan res 
res 
Ori 
galK 
Kan res 
Ori 
A
Figure 2.3: MacConkey assay. 
(A) E.coli cells containing a pMS183-based 2-site recombination substrate were made 
competent and transformed with a pMS140-based low level resolvase expression plasmid. The 
transformants were then spread onto indicator plates containing galactose as a food source and 
an indicator dye which turns red in acidic conditions.  The substrate has a kanamycin resistance 
gene and two recombination sites in direct repeat flanking a galK gene.  In the presence of an 
active recombinase, recombination occurs and the galK gene is excised. The galK-containing 
resolved plasmid has no origin of replication and is lost. In the absence of galK, cells are unable 
to metabolise galactose, giving white colonies. (B) Red colonies formed in the presence of galK 
gene (unresolved substrate). (C) White colonies formed in the absence of galK gene (resolved 
substrate). 
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2.22 Purification of Proteins 
 
Resolvase and TALER proteins were purified using a series of wash steps 
followed by affinity column purification (GE Healthcare, His Gravitrap affinity 
columnsTM) and dialysis.  Expression plasmids with T7 inducible promoters 
(section 3.2, table 2.5) were induced with 200 mM isopropylthio-β-galactoside 
(IPTG) in the E.coli strain BL21(DE3)[pLysS]. Cells from 400 ml culture were 
harvested and broken by sonication (Sonics & Materials, VibraCellTM) by three 
sonication pulses of 15 second duration of cells, while kept cool on ice, in 
fractionation buffer 1 (25 mM inorganic sodium phosphate (NaPi; pH7.6) (a 
3:1 ratio of di-sodium phosphate (Na2HPO4) to monosodium phosphate 
(NaH2PO4)) , 200 mM NaCl, 1 mM EDTA, 100 g/ml PMSF). Centrifugation at 
9000 rpm for 5 mins at 4C was then carried out and the resulting pellet re-
suspended in fractionation buffer 1. Centrifugation was repeated and the 
sample was re-suspended in fractionation buffer 2 (25 mM NaPi, 1 M NaCl, 1 
mM EDTA, 100 g/ml PMSF). This was then repeated for a final time in 
fractionation buffer 3 (25 mM NaPi, 2 M NaCl, 1 mM EDTA, 100 g/ml 
PMSF).  
 
The fractionated samples were then added to nickel affinity (His Gravitrap) 
columns and washed sequentially with 10 ml buffer Q (25 mM NaPi, 20 mM 
imidazole, 1 M NaCl, 6 M urea), 10 ml Buffer B (25 mM NaPi, 20 mM 
imidazole, 2 M NaCl), Buffer W (25 mM NaPi, 100 mM imidazole, 2 M NaCl),  
5 ml Buffer C (25 mM NaPi, 200 mM imidazole, 2 M NaCl), 5 ml Buffer D (25 
mM NaPi, 400 mM imidazole, 2 M NaCl), 5 ml Buffer E (25 mM NaPi, 1.6 M 
imidazole, 800 mM NaCl),  and 5 ml Buffer G (25 mM NaPi, 400 mM 
imidazole, 6 M urea). Purification of Tn3-TALERs was also carried out by 
nickel column wash steps; however, buffers Q and G were not used.  
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
was then used to determine which buffer the protein eluted in (section 2.24). 
Protein samples were then further purified and concentrated by dialysis using 
dialysis tubing. Samples were immersed 1 L each of two buffer changes; first 
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for 16 h in buffer 1A (2 M NaCl, 10 mM NaPi, 0.1 mM EDTA, 200 mg/ml 
PMSF, 1 mM DTT), followed by transfer to the final storage buffer, buffer 2 (1 
M NaCl, 10 mM Tris/HCl (pH 7.5), 0.1 mM EDTA, 50% w/v glycerol). 
 
 
 
 
2.23 Denaturing polyacrylamide gel electrophoresis 
 
SDS-PAGE (Laemmli, 1970) was used to analyse protein samples. The 
protein samples were run through two gel layers of different ionic strength and 
acrylamide percentage. The first gel (stacking gel) was typically 5% 
acrylamide (5% acrylamide/bisacrylimide, 125 mM Tris/HCl (pH 6.8), 0.1% 
SDS, 0.1% APS, 0.2% TEMED), the second gel (resolving gel) was typically 
15% (15% acrylamide/bisacrylimide, 375 mM Tris/HCl (pH 8.8), 0.1% SDS, 
0.1% APS, 0.2% TEMED). The resolving gel was poured between clamped, 
sealed glass plates and covered with isopropanol to exclude oxygen to aid 
polymerisation. When set, the isopropanol was washed off, the stacking gel 
solution was poured in and a well-forming comb was inserted. After 30-40 
minutes of polymerisation, the comb was removed and the gel was inserted 
into a vertical electrophoresis kit. The gels were run in Laemmli 
electrophoresis buffer (25 mM Tris base, 250 mM glycine, 0.1% SDS).  
 
Prior to loading of protein samples, Laemmli loading buffer (50% (v/v) 
glycerol, 5% SDS, 200 mM Tris/HCl (pH 6.8), 0.1 mM DTT) was added at a 
ratio of 1:5 and the samples were heated to 100C for 5 minutes to denature 
the proteins. Samples were then loaded onto the gel and run at 30-40 mA 
(200 V) for 2.5 - 3 hours. 
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2.24 In vitro cleavage assays 
 
In vitro cleavage assays were carried out in a reaction buffer with a final 
concentration of  50mM tris/HCl (pH8.2), 0.1mM EDTA, 40% Ethylene Glycol, 
100mM NaCl and 25g plasmid DNA. 2.2l protein was added to the reaction 
mix and incubated at 37 C for 2 hr. Reactions were stopped by the addition 
of 5 l SDS loading buffer with 1 l Protease K added prior to running on an 
agarose gel (section 2.13.i). 
 
 
2.25 Radioactive labelling of DNA for binding assays 
 
DNA was labelled using either an -32P [dCTP] or a -32P [ATP] source, -32P 
[dCTP] was use for labelling of double stranded DNA fragments from plasmid 
DNA and -32P [ATP] was used for labelling of top-strand synthetic 
oligonucleotides prior to annealing. For labelling with -32P [dCTP], Klenow 
DNA polymerase was used. Labelling reactions were used for double 
stranded annealed oligonucleotides or digested plasmid DNA, and contained 
1x NEB buffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM 
magnesium Acetate, 1 mM DTT), 10-20 M of the 3 unlabelled dNTPs (dATP, 
dGTP and dTTP), 0.37 MBq of  -32P [dCTP] and 1-2 units of Klenow 
polymerase. The labelling reaction was carried out for 10 mins at room 
temperature. The 10 min incubation was followed by addition of unlabelled 
(dATP, dGTP, dCTP and dTTP) to a final concentration of 40 M and a 
further 10 min incubation step.    
 
For -32P labelling, single stranded oligonucleotides were purified by gel 
extraction followed by ethanol precipitation (section 2.12). The concentration 
of the oligonucleotides was then measured and the top strand was 5’ end 
labelled with 32P using T4 polynucleotide kinase (T4-PNK). Labelling 
reactions were typically carried out in 20 l and contained 0.37 MBq -32P 
[ATP], 1x polynucleotide kinase (PNK) buffer, 1 M oligonucleotides and 10 
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Units of T4-PNK. The reaction was carried out for 1 h at 37C, followed by 
heating to 95C for 5 mins. 40 l of TE buffer was then added to the 20 l 
reaction and the solution of labelled oligonucleotide was filtered through a 
column to remove unbound label (GE Healthcare, Illustra Micro Spin G-25 
columnsTM). An excess of bottom strand oligonucleotide (typically 2.2 x), 20 l 
TE buffer and 100 mM NaCl was then added and the sample was heated to 
95C for 10 mins, followed by slow cooling to room temperature to anneal. 
Ethanol precipitation was then carried out (section 2.12).   
 
 
2.26 Gel purification of labelled DNA 
 
For purification of labelled DNA, 1x Ficoll ‘stop mix’ (20% Ficoll, 0.1% SDS, 
0.01% bromophenol blue) was added in a 1:5 ratio and the samples were run 
on a preparative 6% Tris-borate polyacrylamide gel (section 2.13.ii).  The gel 
was then routinely stained with 0.5 g/ml EtBr (section 2.16).  
 
 
2.27 Crush and soak 
 
DNA from acrylamide gel chips cut out from a gel was extracted by crushing 
the gel chip in 500 l TE Buffer. Following overnight incubation with shaking 
at 37C, 1000 rpm (Eppendorf Thermomixer Compact), the sample was 
filtered to remove any remaining gel by centrifugation at 10,000 rpm for 2 min 
using 0.2 M Costar filter columns. The flow-through was collected for ethanol 
precipitation (section 2.11) or phenol/chloroform extraction (section 2.27). 
 
 
2.28 Phenol chloroform extraction 
 
For extraction of DNA from acrylamide gels subsequent to the crush and soak 
protocol, 100 l of a 1:1 ratio of phenol/chloroform was added. Following  
71 
 
centrifugation (13,000 rpm for 1 min) the aqueous phase was transferred to a 
fresh Eppendorf tube, a further 100 l of chloroform was added and mixed by 
vortexing, the centrifugation step was then repeated. The aqueous phase was 
again transferred to a new Eppendorf tube prior to ethanol precipitation of the 
DNA. 
 
 
2.29  In vitro binding assays  
 
Binding was typically carried out in a 20l reaction mix, containing 1x ficoll 
loading buffer (50% v/v ficoll, 200 mM tris/HCl), 20% glycerol, 1 unit of 
Poly(deoxyinosinic-deoxycytidylic) acid and 200 nM labelled Site I DNA. 1l of 
purified resolvase (~30 M) was then added and the reaction mix was 
incubated at room temperature for 20 min, transferred to ice for 10 min and 
loaded onto a 5% polyacrylamide gel with glycerol (section  2.13.ii). Gels 
were typically run at 240V (40mA) for 3 hr prior to the gel being dried and 
exposed overnight to image plates. Plates were scanned using typhoon 
imager.   
 
 
2.30 Crystal structure models 
 
For crystal structure models where more than one structure is used, the 
structures were superimposed using Pymol molecular graphics program. 
Models were typically aligned to the E-helices of resolvase.  
72 
 
Chapter 3: Roles of the E-helix in the DNA-binding and 
synapsis of Sin resolvase  
 
 
3.1 Introduction 
 
WT Sin resolvase binds as a dimer to site I of its recombination site resH 
(section 1.4), but two dimer sites do not interact to form a synapse except in 
the presence of the accessory sites, the accessory bending HU-like protein 
and negative supercoiling (section 1.4). In contrast, the activated Sin mutant 
Q115R binds to isolated site I and forms a synaptic tetramer complex.  
 
In order to find other mutants of WT Sin that are synapsis-competent, an 
assay was carried out by Sally Rowland which was designed to screen for 
mutants of resolvase which showed higher levels of synapsis than the WT 
protein (Sally Rowland, unpublished results). This assay, similar to that 
described in Mouw et al. 2008, was carried out using a library of 
recombination-deficient Sin mutants, with the catalytic serine residue mutated 
to an alanine (S9A), which were screened by transforming into cells 
expressing Cre recombinase and containing a substrate plasmid with two res 
site I sites, and two Cre loxP sites, flanking a galK gene (figure 3.1). In the 
absence of synapsis by Sin, Cre recombinase recombines the loxP sites, the 
galK gene is lost and white colonies are produced on MacConkey indicator 
plates. In the presence of synapsis-competent Sin mutants, synapsis of the 
Sin res sites blocks Cre recombination, giving red colonies on MacConkey 
plates.  
 
The activated mutant Q115R was identified multiple times in this screen, both 
on its own and in conjunction with additional mutations. Interestingly, in 
addition to these mutants, truncated variants of Sin resolvase were also 
isolated from this assay. These variants had premature stop codons, and 
contained activating mutations and were deduced to be creating truncated 
proteins, with the catalytic N-terminal domain absent.  
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These truncated protein variants, (termed ‘tadpoles’), due to the positive 
signal obtained in the assay previously described (Sally Rowland unpublished 
results) were hypothesised to be forming synaptic complexes, despite the 
absence of the N-terminal domain (~100 residues). It was hypothesised that 
these ‘tadpole’ constructs bind to and dimerise on site I DNA in the same way 
as WT Sin and that the E-helices make a synapsis interface like that seen in 
the core of the crystal structures (figure 3.2A). This same 4-helix bundle is 
present in other members of the recombinases family, including  resolvase 
(figure 3.2B). The conserved nature of this helix-bundle suggests that it may 
form a ‘synapsis module’, the minimum architecture required to hold the 
dimers together and permitting subunit rotation to take place following 
synapsis.  
 
As the ‘tadpole’ proteins are WT in sequence, but are nonetheless capable of 
synapsis unlike the full-length WT protein, it can also be deduced that the 
catalytic N-terminal domains of Sin (and ) resolvase have a negative 
regulatory role, blocking E-helix interactions with each other (and thus 
synapsis) unless the correct synapsis complex is formed in the full WT 
system.   
 
Following on from the discovery of these ‘tadpoles’, this chapter will discuss 
the purification and testing of three lengths of truncated Sin variants, with 
deletions of the first 100 residues (101), 108 residues (109) and 123 
residues (124). The 109 protein was isolated in the initial synapsis-up 
screen, the longer, 101 and the shorter 124 protein lacking the E-helix 
region were created to determine the importance of the E-helix to synapsis 
(figure 3.3). 
 
The properties of these ‘tadpole’ proteins were determined using in vitro 
binding and synapsis assays, as described by Olorunniji et al (2008) and 
Rowland et al (2009). 
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Figure 3.2: Resolvase ‘synapsis module’ 
Crystal structures illustrating the catalytic domains and E-helices of (A) Sin 
resolvase (3PKZ, Keenholtz et al. 2011) (B)  resolvase (1ZR4, Li et al. 
2005) and the 4-helix bundle at the core of the catalytic tetramers forming 
the hypothesised ‘synapsis module’.    
A 
 
 
 
 
 
 
B 
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As the ‘tadpoles’ are predicted to recognise the site I DNA in the same way as 
the ‘activated’ full-length Sin/Tn3/ proteins (see section 1.2), the interaction 
between the DNA within the minor groove of the site and the ‘arm’ region of 
the protein should be an important one. As such, the effect of ‘swapping’ the 
arm region of full-length and ‘tadpole’ Sin proteins with the equivalent 
residues from Tn3 resolvase which naturally interact with a very different 
central sequence was tested. It was predicted that these hybrid proteins 
would fail to interact with the Sin site I, but may have the ability to form a 
synapse at a hybrid site I, with the relevant residues replaced with sequence 
from Tn3 site I.       
 
The properties of the WT ‘tadpole’ variants were also compared with point 
mutants within the E-helix, selected based on the available crystal structure 
data, to be informative about the mechanism of synapsis. These assays 
aimed to determine whether the synapses formed by the tadpole variants are 
structurally similar to the synapses formed by the assembly of the four-helix 
bundle seen in  and Sin crystal structures. These mutations were also 
introduced into the full-length Q115R Sin protein, with the hypothesis that 
they will have an effect on binding and recombination consistent with the 
effects on ‘tadpole’ synapsis. Q115R was utilised for this purpose, as it is the 
single strongest activating mutation in Sin, and is known to be synapsis-
competent in vitro.    
 
 
3.2 Sin ‘tadpole’ design and construction 
 
The three ‘tadpole’ proteins utilised in this study, 101, 109 and 124 were 
created by fragment-swap or by insertion of oligonucleotides into pre-existing 
vector plasmids. High copy number plasmids (pSA1101-type with inducible 
T7 promoters, see table 2.5) were constructed for in vitro expression of Sin 
resolvase and the ‘tadpole’ proteins. The WT 101 protein was created by 
ligation of oligonucleotide SEH1 (see table 2.4) into T7 inducible high copy 
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number expression vector pSA1171 (full-length Sin, see table 2.5) between 
the restriction sites NdeI and NcoI. The WT 109 expression vector was 
created by AlwNI–NcoI fragment swap between the expression vectors 
pSA1171 and pSA1195 (109 V138A Sin, see table 2.5) and the shortest 
truncated variant, 124 was created by fragment swap between pSA1171 
and pSA1196 (124 V138A Sin, see table 2.5) as illustrated in figure 3.4. 
Each of these proteins has a histidine tag (his6) C-terminal to the DNA-
binding domain as shown in figure 3.3. Following creation of these vectors as 
described, the plasmids were transformed into the E.coli strain BL21 (DE3) 
[pLysS] (see table 2.5) using the chemically competent transformation 
method described in section 2.8-2.9.  These cells were then grown to mid-log 
phase, as determined by spectrophotometry, and induced by addition of IPTG 
(as in section 2.22).  
 
Protein induction was visualised by SDS-PAGE, with un-induced and induced 
samples visualised by staining with coomassie brilliant blue staining (figure 
3.5A).  The cells were pelleted and the samples fractionated (as described in 
section 2.22). The fractions were visualised by SDS-PAGE and the best 
sample was selected for purification by nickel column chromatography using 
the C-terminal his6 tag (section 2.22).   
 
Following nickel column purification, further SDS-PAGE was used to 
determine the best sample to further purify and concentrate. This sample was 
then dialysed (as described in section 2.22) to concentrate the sample and 
yield a sample in 50% glycerol buffer for storage at -70C (figure 3.5B).  The 
concentrations of the protein samples were determined by visualisation on 
polyacrylamide gels, followed by normalisation to the protein of lowest 
concentration. 
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Figure 3.4: Expression plasmid construction 
Construction of high copy number IPTG-inducible ‘tadpole’ expression vectors. 
(A) 101 construction by ligation of the oligonucleotide SEH1 into pSA1171 
(NdeI-NcoI). (B) 109 construction by fragment-swap between pSA1171 and 
pSA1195. (C) 124 construction by fragment-swap between pSA1171 and 
pSA1196. 
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  Tadpoles   Tadpoles 
A                                                        B            
Figure 3.5: SDS-PAGE  
(A) Protein samples prior to (U) and following induction (I) with IPTG, showing 
expression of the ‘tadpole’ proteins. (B) The ‘tadpole’ constructs following 
column purification and dialysis. 
   
 101        109        124 
U       I      U      I      U      I                                       101 109 124 
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3.3: Binding and synapsis of res site I 
 
The ‘tadpole’ proteins were tested for binding and synapsis to res site I. For 
the purpose of these experiments, a symmetrised Sin site I variant (RSinR) 
was utilised, with the left hand side of the site symmetrised to the right side of 
the site, as previous research has indicated that the binding affinity for the 
right half of the site is better than that of the left half (Sally Rowland and 
Martin Boocock unpublished data) (figure 3.6A). This RSinR substrate was 
thus predicted to be a better substrate for these in vitro assays, as it should 
bind to the site with greater affinity than the LSinR site. Linear substrates, 45 
bp in length, with the 30 bp RSinR substrate in the centre, were ordered as 
oligonucleotides (SEH 52-T and SEH 52-B from table 2.4) from Eurofins 
MWG Operon (figure 3.6B).        
 
For visualisation of protein-DNA complexes in vitro, purified top strand 
oligonucleotide (SEH 52-T) was 5’ end-labelled with -32P ATP (section 2.24) 
and annealed to the bottom strand (section 2.18). Binding assays were 
typically carried out using gels with 7% acrylamide/bis-acrylamide (30% w/v, 
37.5:1) and 10% glycerol, run with TBE buffer (section 2.13.iii). Glycerol was 
added to the gels as it was determined that this increased the stability of the 
protein-DNA complexes on the gel. Gels were routinely run at 4 C for 4-5 hrs 
at 200 V (~15 W). These binding assays typically utilised unbound DNA as a 
control for band-shift of complexes.  
 
These assays used full-length Q115R Sin as a control, as this activated 
mutant has been demonstrated previously to form monomer, dimer and 
tetramer structures on polyacrylamide gels. Three sizes of retarded protein-
DNA complexes were visualised in these assays (figure 3.7). The full-length 
Q115R Sin produced the predicted three bands, as previously established. 
The longest of the truncated proteins, the 101 ‘tadpole’ formed only the 
slowest migrating band, hypothesised to be a synaptic tetramer structure, 
based on the band-shift position relative to the full-length protein complexes.  
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Figure 3.7: In vitro binding assay  
In vitro binding assay with P labelled RSinR site I DNA substrates bound by 
full-length Q115R Sin and by the truncated ‘tadpole’ constructs; M101, M109, 
M124 and a no protein control (Bl).   
    
 
Unbound DNA 
Monomer 
Dimer 
 Tetramer 
Bl   124   109  101 
RSinR site I 
  Full 
Q115R 
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The 109 ‘tadpole’ formed three complexes on the gel, hypothesised to be 
monomer, dimer and tetramer complexes. An additional, faster migrating 
band is also present on the gel, which may be an altered conformation of the 
tadpole. The shortest 124 ‘tadpole formed the fast and intermediate running 
complexes but not the slowest, indicating that it is able to form the 
hypothesised monomer and dimer complexes, but not the tetramer structure 
hypothesised as the slowest migrating complex on the gel.  
 
The slowest migrating of these complexes is thus hypothesised to contain two 
DNA molecules bound by a tetramer of Sin, the intermediate complex is 
hypothesised to have one molecule of DNA bound by a dimer of Sin and the 
fastest running complex is hypothesised to contain one molecule of DNA 
bound by a monomer of Sin.   
 
If the hypothesis that the slowest migrating bands seen for the 101 and 
109 ‘tadpoles’ in figure 3.10 represents a synapse analogous to that seen in 
the full-length Q115R Sin is correct, then the complex must contain two 
molecules of DNA bound by four subunits of resolvase. In order to test the 
validity of this hypothesis, a further binding assay was designed, utilising two 
different lengths of DNA (45 bp and 77 bp) with the 30 bp RSinR res site I at 
the centre (figure 3.8).  
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Each DNA molecule (45 bp or 77 bp) was either labelled with 32P (*) or left 
unlabelled. Linear DNA molecules of 45 bp and 77 bp (45 + 77 and 45* + 77* 
respectively) and the 109 ‘tadpole’ were utilised for this experiment. The full-
length WT Sin, similar to WT Tn3 resolvase, has been shown to form only 
dimer in vitro (Rowland et al 2009) and would be expected to form two distinct 
bands in this assay, one with 45* and one with 77*.  
 
This assay tested the 109 protein, with full-length WT Sin as a control (figure 
3.9). The full-length WT, as expected, forms dimer complex on the gel, 
visualised as two bands (a 45* DNA molecule bound by a dimer of Sin or a 
77* DNA molecule bound by a dimer of Sin). The 109 ‘tadpole’ forms the 
three bands anticipated for the presence of a tetramer like that seen in full-
length Q115R Sin; two 45* DNA molecules bound by a tetramer of Sin, a 45* 
and a 77 DNA molecule, or a 45 and a 77* DNA molecule bound by a 
tetramer of Sin or two 77* DNA molecules bound by a tetramer of Sin. This 
result confirmed that the large complex formed by the 109 ‘tadpole’ proteins 
contains two molecules of DNA as hypothesised for the predicted tetramer 
complex.  
 
 
3.4 Sequence selectivity of res site I 
 
Having demonstrated that the ‘tadpole’ constructs are forming a synapse 
analogous to that formed by the full-length activated mutant Q115R Sin, it 
was next desirable to determine whether there is any sequence selectivity at 
the centre of the site, and what effect if any changing this sequence would 
have on binding and synapsis of this site.  In order to test the importance of 
the site sequence to binding and synapsis, a half-site (R) was designed 
(figure 3.10), with the right hand side of Sin as normal, and the left hand side 
of the site altered to residues selected to be as different from the right hand-  
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Figure 3.9: In vitro band-shift assay  
Assay showing binding of 109 Sin ‘tadpole’ to RSinR site I substrates 
of 45 bp and 77 bp. 32P labelled site I (45* & 77*) and non-labelled site I 
(45 & 77) were used. (B) Band-shift assay showing binding of full-length 
Sin to RSinR site I substrates. No protein controls (Bl) are also shown. 
 
Bl               109 Sin 
45* 45*  77* 77*     
  -    77   45   - 
 45* 77*     
   -     - 
RSinR 
 45* 77*     
   -     - 
Bl       Full WT Sin 
45*  45*  77*  
 -     77*    -   
RSinR A                                            B 
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side sequence as possible, a sequence predicted to be an undesirable Sin 
binding sequence. This sequence was ordered from MWG as top and bottom 
strand oligonucleotides (SEH 51-T and SEH 51-B, table 2.4). If, as 
hypothesised, the sequence of the site is important to binding, the R site 
would be predicted to be bound by a monomer of Sin at the right hand side of 
the site only. 
 
The R top strand oligonucleotide was 5’ end -32P ATP labelled and 
annealed to the bottom strand as described in section 2.24. Binding and 
synapsis assays were then carried out as with the RSinR assays previously 
discussed. Polyacrylamide gel electrophoresis under the conditions described 
in section 3.3 was carried out to test binding to the R site I (figure 3.11). It 
was observed that the R site as hypothesised is able to form only 
monomeric interactions with Sin, illustrating that both the right and left halves 
of the site are required for dimer and synapse formation, such as that seen 
with the RSinR substrate.  
 
Once it had been determined that both halves of the site are necessary for 
any interactions involving more than one Sin subunit, the effect of replacing 
the sequence at the centre of the site was tested. This was achieved by 
altering the central 10 bp of the 30 bp site from the Sin res site I residues to 
Tn3 sequence, creating an RTn3R substrate (figure 3.12).  
 
As for the RSinR and R substrates, the RTn3R sequence was ordered from 
MWG as top and bottom strand oligonucleotides (SEH 50-T and SEH 50-B, 
table 2.4) If the sequence at the centre of the site is important to binding, then 
the alterations made to the sequence in the RTn3R substrate would be 
predicted to disrupt binding of the ‘tadpole’ constructs.   
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The RTn3R top strand oligonucleotide was 5’ end -32P ATP labelled and 
annealed to the bottom strand as described in section 2.24. Binding and 
synapsis assays were then carried out as with the binding assays previously 
discussed for RSinR and R. Polyacrylamide gel electrophoresis under the 
conditions described in section 3.3 was carried out to test binding to the 
RTn3R site I (figure 3.13). This experiment used full-length WT Sin as a 
control for binding. It was observed that the RTn3R site behaved mostly as 
predicted, blocking the normal interactions seen with the full-length and 
‘tadpole’ proteins on the RSinR site.  
 
The full-length WT, the 109 and 124 ‘tadpoles’ as hypothesised bound to 
the site as monomer only. The longest of the ‘tadpole’ constructs however 
shows evidence of a tetramer complex on the gel. This complex appears 
unstable however.  The detrimental effect on the normal complexes seen on 
binding with the RTn3R substrate demonstrates that the central sequence, at 
the position where the ‘arm’ region of the E-helix crosses the DNA, is 
important to binding of the site and subsequent synapsis. 
 
 
3.5: Sequence selectivity by the E-helix ‘arm’ of resolvase 
 
If this region, within the central 16 bp of the res site I sequence is making 
specific interactions with the ‘arm’ region of Sin resolvase, then hypothetically 
it should be possible to swap the ‘arm’ region of Sin resolvase with the 
equivalent residues from Tn3 resolvase (Sin residues 132-146, Tn3 residues 
126-140) (figure 3.14). This should create a hybrid protein which is unable to 
stably bind to the RSinR substrate, but may have the ability to bind to and 
synapse the hybrid site.   
Hybrid Sin proteins with the ‘arm region of Tn3 were constructed by insertion 
of annealed oligonucleotides from MWG (SEH4-T and SEH4-B, table 2.4) 
between the restriction sites SalI and BamHI of the relevant pSA1121-type 
plasmid (full-length Q115R, 101 or 109 Sin).  
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Plasmids expressing these proteins were chemically transformed (section 
2.9.i) into BL21 (DE3) [pLysS] cells (table 2.1), and expressed and purified as 
described in section 2.22.  When tested for binding capability with the RSinR 
substrate by polyacrylamide gel electrophoresis under the conditions 
previously described in section 3.3 (figure 3.15), the 109 ‘tadpole’ with the 
‘arm’ residues 132-146 altered to the equivalent Tn3 residues (109/Tn3) was 
observed to be unable to form dimer and tetramer interactions. As predicted, 
alteration of the ‘arm’ region knocks down binding and synapsis in this hybrid. 
The hybrid 101 ‘tadpole’ (101/Tn3) appears to retain the ability to bind as a 
tetramer to this site; however this complex runs at a faster rate on the gel, 
suggesting an altered, more compact protein complex conformation.  
 
The full-length Q115R Sin with the altered ‘arm’ region (Q115R/Tn3), similarly 
to the 109 hybrid ‘tadpole’ was observed to lose the ability to form a tetramer 
with the RSinR site.   
 
To determine whether alteration of the res site centre to Tn3 sequence is able 
to rescue this phenotype, (as may be predicted if this ‘arm’ region is 
specifically interacting with the DNA), the hybrid proteins were also tested for 
binding of the RTn3R substrate. This assay (figure 3.16) showed less of an 
effect than had been hypothesised. The hybrid full-length Q115R protein 
which formed dimer (but not synapse) on the RSinR substrate is also 
observed to form only dimer complex on the RTn3R substrate. The 109 
‘tadpole’ is similarly unaffected by the alteration of the central sequence of the 
site. The 101/Tn3 hybrid may form a slightly more stable tetramer complex 
than the 109 WT ‘tadpole’ as there is less unbound DNA observed in the 
hybrid than in the WT protein. The effect of altering the E-helix and the site to 
Tn3 sequence was not as marked as was predicted in vitro. 
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            109/             101/             QR/ 
   109   Tn3   101    Tn3     QR     Tn3         BL     124  
Tetramer (tad)  
Dimer (full QR)  
Monomer  
RTn3R 
Figure 3.16: In vitro binding assay of Sin ‘tadpoles’ with and without Tn3 E-
helix ‘arm’ swap 
In vitro binding assay showing binding of 58 bp 32P labelled RTn3R Site I by 124, 
109 and 101 tadpole constructs, 101/Tn3 and 109/Tn3 and full-length Q115R 
and full-length Q115R/Tn3 constructs (QR) with the E-helix arm residues altered from 
Sin to Tn3 residues (as described in section 3.2).   
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The in vivo effect of these alterations on the ability of the full-length proteins 
to carry out recombination was then assayed using MacConkey indicator 
plates (as described in section 2.21).  In vivo 2-site recombination substrates 
were constructed by a four piece fragment swap between a pMTL23-type 
substrate containing a single copy of the site and pMS183 (table 2.5). This 
construction uses restriction fragments BamHI-Asp718 and XbaI-NcoI from 
the pMTL23-type plasmid and BsrGI-Xba and NcoI-BglII, utilising the 
compatibility of BamHI/BglII and BsrGI/Asp718 (figure 3.17).  
 
Assays were carried out in vivo with these substrates on MacConkey indicator 
plates (figure 3.18). It was observed that the RSinR site I substrate was 
recombined efficiently by Q115R Sin, while the substrates with Tn3 sequence 
alterations at the centre (RTn3R) and the half-site (R) are not recombined. 
The hybrid enzymes with the ‘arm’ region of the E-helix replaced by the 
structurally equivalent residues from Tn3 resolvase, as discussed in the 
previous section, were also tested. The results of this assay agree with the in 
vitro observations, as the hybrid failed to recombine the RTn3R substrate 
(figure 3.18).  
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      resolvase     _ 
     + resolvase 
Figure 3.17: In vivo recombination substrates and products of recombination 
Construction of low copy number in vivo substrate plasmids containing two copies of 
RSinR site I flanking a galK gene and a kanamycin resistance gene. (A) Plasmids 
were constructed by a four-piece ligation of XbaI-Asp78I + NcoI-XbaI fragments from a 
plasmid with a single copy of RSinR site I (pSE1005) and BsrGI-XbaI + BglII-NcoI 
fragments from the galK containing plasmid (pMS183).  (B) Outcomes in the 
presence and absence of resolvase. Unresolved substrate (galK +) produces red 
colonies, resolved substrate (galK -) produces white colonies. 
pSE1012 
  RSinR 
pMS183 pSE1005 
  RSinR 
A  
 
 
 
 
 
 
 
 
B 
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  RSinR                      RTn3R                         R 
    Q115R  
       Sin 
 
 
 
 
 
Q115R/Tn3  
      Sin 
Figure 3.18: In vivo recombination assay  
In vivo MacConkey assay, testing the ability of Q115R Sin to recombine the 
RSinR, RTn3R and R 2-site in vivo recombination substrates as described 
in section 2.7.v with a galK gene flanked by two res site Is. White colonies 
represent successful recombination and red colonies contain un-recombined 
substrate.  
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3.6 Mutations of the Sin E-helix 
 
In order to determine which of the individual residues in the E-helix region are 
required for protein-protein interactions, the crystal structure of Sin was 
examined, and residues were selected which in the structure appear to be in 
positions which may have an effect on tetramer formation. Residues L112, 
I116 and M119 were selected as having potentially important roles in 
synapsis due to their location on the flat interface of the E-helices in the 
tetramer structure (figure 3.19A). These residues also make contacts 
between pairs of anti-parallel E-helices in the ‘rotational dimers’, an interface 
with importance for synapsis. 
 
The positioning of these residues in the crystal structures suggests that they 
may play a role in facilitation of the subunit rotation at this interface. Residues 
were also selected in a structure- guided manner which do not sit on the flat 
tetramer interface and therefore might be expected to be less important, due 
to their positions in the structure, appear to be less significant for synapse 
formation. These residues; K110, I114 and S121 (figure 3.19B) were also 
mutated and the mutants tested for binding and synapsis ability.  
 
K110 is located on the outer face of the E-helix, in a position where it does 
not contact the E-helix of the other resolvase subunit (figure 3.20B). However 
it appears to have interactions with the catalytic domain. L112 is positioned 
on the internal surface of the E-helix, in the flat interface between the helices 
(figure 3.20C). I114, similarly to K110, is on the external face of the E-helix, 
with E-helix/catalytic domain interactions (figure 3.20D). Residues I116 and 
M119 are situated directly in the centre of the E-helix interface, in a position 
hypothesised to be important for the synapsis interface (figures 3.20E and 
3.20F). The final residue selected to be mutated; S121 is in a position outside  
the E-helix interface, this also has E-helix/core interactions, but would 
hypothetically have little effect on synapsis (figure 3.20G). 
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A                                                    B                        C 
D                          E                        F                       G 
K110 
L112 
I114 
I116 
M119 
S121 
Figure 3.20: Crystal structure of the Sin E-helix 
(A) The crystal structure of Sin resolvase tetramer catalytic domains and E-
helices, showing the position of; (B) residue K110 on the exterior of the interface, 
(C) residue L112 on the interior of the interface, (D) residue I114 on the exterior of 
the interface, (E) residue I116 on the interior of the E-helix interface, (F) the 
position of residue M119 on the exterior of the interface  and (G) residue S121 on 
the interior of the E-helix interface. Figure made using 2R0Q (Mouw et al 2008). 
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The chosen E-helix residues were individually mutated to alanine using 
synthetic oligonucleotides (SEH32-SEH45; table 2.4). Each mutation was 
introduced into a 109 ‘tadpole’, which was otherwise WT in sequence, and 
also into full-length Q115R Sin. Alanine was chosen as the residue to replace 
the natural residue as there is much precedence in the literature for its use in 
such assays (Morrison et al. 2001). Alanine has a relatively small side chain 
and is not disruptive to protein structure, therefore negating the chance that 
any observed effect is due to disruption of protein folding rather than the 
importance of the residue being altered.  
 
Oligonucleotides ordered from MWG were cloned into pSA1121-type T7 
inducible expression vectors already containing 109 ‘tadpole’ constructs 
between the restriction sites NdeI-NcoI (SEH32, 33, 34, 35; table 2.4) or 
NdeI-SalI (SEH36, 37; table 2.4), or vectors containing full-length Sin 
between BstEII-NcoI (SEH40, 41, 42, 43; table 2.4) or BstEII-SalI (SEH44, 
45; table 2.4). Vectors were then cloned into BL21 (DE3) [pLysS] cells and 
induced, and the proteins expressed (figure 3.21) and purified as described in 
section 2.22.  
 
 
3.6.i: In vitro binding of E-helix mutants 
 
Binding assays were carried out in vitro using 32P-labelled linear site I DNA 
constructs and purified full-length and 109 tadpole versions of the E-helix 
mutant proteins (sections 2.25 & 2.23). These in vitro binding assays were 
designed to test two hypotheses; first, that the Sin ‘tadpole’ mutants are 
directly comparable in their behaviour and the structures which they are able 
to form with their full-length Q115R counterparts, and second, that the E-helix 
mutations selected on the basis of crystal structure data do in fact retain or 
reduce synapsis capability as predicted, that is, that the mutations on the 
crystallographic synaptic interfaces reduce or abolish synapsis, whilst those 
that are not on the interfaces have less of an effect or no effect. 
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   109           109          109          109          109            109 
  K110A        L112A         I114A         I116A        M119A        S121A 
 U        I        U        I       U        I       U        I       U        I       U        I 
 
 Full QR       Full QR      Full QR      Full QR      Full QR       Full QR 
  K110A        L112A         I114A         I116A        M119A        S121A 
 U        I        U        I       U        I       U        I       U        I       U        I 
 
Figure 3.21: SDS PAGE showing induced and un-induced proteins 
Polyacrylamide gel showing; (A) Un-induced (U) and induced (I) truncated 
‘tadpole’ proteins with E-helix mutations (left) and the same proteins following 
purification (right). (B) Un-induced (U) and induced (I) full-length proteins with E-
helix mutations (left) and the same proteins following purification (right). 
     QR       QR        QR       QR        QR 
   L112A   I114A   I116A  M119A  S121A 
 
 
  109    109    109    109      109    
L112A   I114A   I116A  M119A  S121A 
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The ‘tadpole’ mutant binding assays were carried out as described for 
previous binding assays. This assay (figure 3.22), showed that the 
109/L112A mutant, contrary to the predicted result, retains the ability to form 
a tetramer complex. The observed result for the 109/I114A mutant supports 
the hypothesised result, with the mutation having no effect on the ability to 
form tetramer. Similarly, the 109/I116A mutants act as hypothesised from 
the crystal structure, being unable to form a synapse on the gel, showing that 
this residue on the E-helix interface is important for formation of the synapse.   
The 109/M119A mutant, which was hypothesised from the crystal structure 
data to be unable to form tetramer was shown to form stable dimer structures, 
but, as predicted, does not form a synaptic complex. The final ‘tadpole’ 
mutant tested, 109/S121A, located on the outside of the E-helix interface 
was also observed to agree with the predicted result, as this mutation had no 
effect on the ability of the protein to form a synapse.  
 
The ‘tadpole’ E-helix mutants were largely observed to behave as predicted 
from the crystal structure data. It was next desirable to test the effect of these 
mutations in a full-length Q115R background to determine whether, as 
hypothesised, the ‘tadpole’ constructs are analogous to full-length activated 
Sin. 
 
Binding assays, again utilising the same gel conditions previously discussed 
were carried out. This binding assay (figure 3.23) showed that the full-length 
Q115R/L112A mutant, as predicted from crystal structure data, is able to form 
monomer and dimer complexes, but not tetramer. The full-length and 109 
I114A mutant variant also supports the hypothesised result, with the mutation 
having no effect on the ability to form tetramer.  
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The full-length Q115R/I116A and Q115R/M119A mutants, which were 
hypothesised to be unable to form tetramer were shown to form stable dimer 
structures, but, as predicted, do not form a synaptic complex. The I116A 
dimer complexes run at a faster rate on the gel, indicating that a more 
compact structure is formed by this residue change. The full-length 
Q115R/S121A mutant, located on the outside of the E-helix interface was 
also observed to agree with the predicted result, as this mutation had no 
effect on the ability of the protein to form a tetramer.  
 
These binding assays testing ability of the ‘tadpole’ and full-length E-helix 
mutants to bind and form a synapse showed that all of the E-helix mutants, 
with the exception of the 109/L112A mutant behaved as predicted from the 
crystal structure data. The full-length L112A and both variants of I116A and 
M119A mutant, located on the E-helix interface, as hypothesised are 
detrimental to the formation of synapse. The 109/L112A mutant was 
observed to retain the ability to form a tetramer; this could be due to the 
position of the mutation near to the N-terminus of the truncated protein. The 
mutants on the outside of the E-helix interface, again as hypothesised were 
all observed to have no effect on the ability of the protein to form synapse.   
    
 
3.6.ii In vivo recombination by E-helix mutants of Sin 
 
Having determined the effect of the mutations on the binding and synapsis 
capabilities of the ‘tadpole’ and full-length mutants, the next step was to 
determine the effect of the mutations on the ability of Sin to carry out 
recombination. 
 
In vivo recombination assays utilising the 2-site RSinR substrates described 
in section 3.5 showed that the L112A, I114A, I116A and M119A mutations 
prevent catalysis of recombination by Q115R Sin (figure 3.24). The K110A 
mutant shows a knock-down in recombination efficiency, and S121A has no 
effect on the recombination ability of the protein.  
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These results mostly agree with the in vitro binding results. The I114A mutant 
is able to form a tetramer, and yet is unable to catalyse recombination in vivo. 
However, perhaps it is not unexpected that the I114A mutation has 
detrimental effects on recombination activity due to the close proximity of this 
mutation to the single activating mutation (Q115R) which may be causing a 
slight conformational change, negatively impacting on the hyperactivity of the 
Q115R mutant; the WT protein is synapsis-deficient at site I in the absence of 
the accessory sites.  
 
 
3.7 Discussion 
 
In this chapter, the sequence selectivity of Sin resolvase-mediated binding 
and synapsis of site I was tested by assaying the effect of alteration of the 
nucleotide sequence at the centre of the site and by testing three truncated 
variants of Sin (101, 109 and 124) on these altered site I sequences to 
determine the effect of these changes on protein-protein and protein-DNA 
interactions. It was shown that altering the nucleotides at the centre of site I 
from the Sin nucleotides to the corresponding Tn3 nucleotides (RTn3R) has a 
negative effect on binding by Sin, showing that these nucleotides are 
recognised by the protein and required for strong binding of the site. The R 
‘half-site’ was also informative, as it demonstrated the specificity of binding by 
only a monomer of Sin. 
 
Assays with the truncated ‘tadpole’ variants showed that 101 and 109 were 
competent for binding and synapsis, but deletion of the residues between 109 
and 124 of the E-helix in 124 prevented the formation of a synapse. This 
result indicated that residues in this area of the protein are required for 
formation of a tetramer of E-helices. 
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The 109 and 124 proteins with altered Tn3 ‘arm’, as predicted if this region 
as hypothesised confers sequence selectivity, were not able to form a 
synapse at the RSinR site, thus demonstrating that residues within the E-helix 
‘arm’ region do have specificity for binding at the site. The 101 Tn3 ‘arm’ 
mutant however was shown to be able to form a tetramer in vitro, which may 
be due to co-operative binding and the E-helix interactions of the protein 
conferring stability to the protein. These mutants of Sin with alterations to Tn3 
‘arm’ residues were also shown to be unable to form tetramer complexes or to 
recombine the RTn3R site. This is not as predicted, as it was hypothesised 
that the alteration of the nucleotides at the centre of the site might be able to 
rescue the ability to form tetramer complexes. This result may be due to 
deletion of conserved Sin residues which bind at the centre of the site, which 
are essential for the recombination reaction.  
 
The E-helix mutants discussed in section 3.6 were tested in both a full-length 
Q115R Sin background and in a 109 ‘tadpole’ background. This was to test 
two hypotheses, first, that the ‘tadpole’ variants behave analogously to the 
full-length Q115R variants, based on the hypothesis that the E-helix bundle at 
the centre of the tetramer acts as a basic synapsis module, which is synapsis-
competent, and secondly to determine whether the selected E-helix mutations 
have an effect on synapsis in these backgrounds.  
 
It was determined that the ‘tadpole’ proteins do indeed behave in a very 
similar way to the full-length Q115R proteins; an interesting result, as these 
truncated proteins may make it easier to study binding and synapsis by 
resolvase free from the catalytic domains. The E-helix mutations were shown 
to behave largely as hypothesised, with the three mutations on the interior of 
the E-helix interface (L112A, I116A and M119A) preventing synapsis in vitro 
and recombination in vivo, and the mutations which do not sit on this interface 
(K110A, I114A and S121A) having no effect on binding in vitro.  
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There were however two anomalies in the behaviour of the proteins; firstly, 
the I114A mutant, although shown to form synapse in vitro, was unable to 
carry out recombination in vivo. This may be due to the proximity of this 
mutation to the important activating mutation Q115R, disrupting its effects. If 
this mutation is being negated, this would be an expected result, as the WT 
Sin protein is inactive in this site I x site I assay (Rowland et al. 2009).  
 
The only differing result between the 109 and full-length mutants was the 
L112A mutant, which was shown to be unable to form synapse in the full-
length construct as hypothesised, but which was shown to retain synapsis 
ability in the ‘tadpole’. This may be due to the location of this residue near the 
N-terminus of the truncated variant, which may give this protein a greater 
level of flexibility, allowing it to form synapse despite the mutation, by 
interactions of other hydrophobic residues near the N-terminus.  
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Chapter 4: TALE Recombinases 
 
 
4.1 Introduction 
 
The modular nature of the serine recombinases allows the DNA binding and 
catalytic functions of the protein to be structurally independent of each other, 
permitting the functional replacement of the DNA-binding domain with that of 
another protein. This has been demonstrated by the zinc finger 
recombinases, which combine the catalytic abilities of resolvase with the 
DNA- binding domain of a zinc finger protein, as discussed in section 1.6.iv.  
 
This chapter describes research carried out with the aim of creating functional 
chimeric recombinases using a different modular DNA-binding domain, from 
Transcription Activator-Like Effector (TALE) proteins. This approach utilises 
an activated mutant of Tn3 resolvase (Tn3-NM), described in section 1.2.ii.  
 
 
4.1.i TALE proteins 
 
TALEs produced by bacterial pathogens in the Xanthomonas sp. act naturally 
as transcriptional activators of virulence genes, conferring pathogenicity 
through specific recognition of promoter sequences (Boch et al 2010). What 
makes TALEs potentially very useful as tools for DNA targeting is their ability 
to recognise DNA specifically, utilising a central repeat domain consisting of a 
series of nearly identical repeats, each typically 34 amino acids in length, 
which usually differ only at positions 12 and 13, a region known as the repeat 
variable di-residue (RVD). This hyper-variable region is responsible for 
specific recognition of the sense strand of the DNA, with position 12 providing 
stability to the repeat structure while position 13 confers recognition of one 
base of the DNA with varying degrees of fidelity (figure 4.1), (see also section 
1.6.iii).  
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% 
bound 
Figure 4.1: DNA recognition by TALE RVDs 
Nucleotide recognition by the most common natural RVDs, from TALEs isolated from 
Xanthomonas sp. (A) Crystal structure showing the repeat fingers wrapping around the 
DNA, with RVDs (red sticks) positioned in the centre (B) Crystal structure of five common 
RVD at positions 12 (shown as lines) and 13 (shown as sticks), illustrating their DNA 
recognition (from 3UGM crystal structure (Mak et al. 2010)) (C) Chart created based on 
DNA recognition by the RVDs of the TALEs: AvrXa27, PthXo1, PthXo6, PthXo7, AvrBs3, 
AvrBs3rep16, AvrBs3rep109, AvrHah1 and Tal1c. (Based on RVD alignments from 
Moscou and Bogdanove 2009). 
NI=A HD=C NG=T NN=G 
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These repeats can be re-arranged to recognise any sequence, allowing 
creation of proteins with desired DNA-binding speciﬁcities. This has already 
been used successfully for the creation of TALENs, by fusing a FokI nuclease 
domain to a TALE DNA-binding domain, as discussed in section 1.6.iii. 
 
This study employs the available crystal structures of the two TAL effectors; 
PthXo1 bound to DNA (pdb: 3UGM; Mak et al. 2012) and dTale2 (pdb: 4HPZ; 
Gao et al. 2012). Both of these models were utilised as their sequences are 
very similar to the TAL used in this work and are thus useful in order to design 
TALER constructs. The PthXo1 TALE DNA-binding domain has a 22-finger 
DNA recognition module with two additional imperfect repeat fingers (fingers 
0 and -1) N-terminal of the RVD-containing repeats and an additional half-
repeat at the C-terminus (termed finger ½) which is also involved in DNA 
recognition. DNA recognition by the RVDs is shown in figure 4.2. This crystal 
structure is disordered before residue 221 (the -1 finger in this structure 
beginning at residue 219), however, the more recent crystal structure of 
dTale2 revealed that there is structured protein N-terminal of this -1 finger, 
revealing a further two imperfect repeats, termed -2 and -3, which form a 
structure similar to the  -1 finger.  This crystal structure has a much smaller 
TALE DNA-binding domain, with only 9 RVD-containing repeats (figure 4.3). 
No crystal structure to date exists with structure N-terminal of this -3 finger. 
 
The TALE DNA-binding domain utilised in this study (hey2) was selected 
because it has previously been shown to target a TALE nuclease (TALEN) 
successfully to its designed site within the zebrafish genome (Sander et al 
2011), so we predicted that it could also act to target a TALER to similar 
sequences. This TALE DBD consists of a ‘+63’ architecture, as described by 
Miller et al (2011) with 63 residues C-terminal of the central repeat structure 
and 17 RVD containing repeats, which recognise a 17 bp DNA sequence, 
preceded by the conserved thymine, as discussed in section 1.6.iii (figure 
4.4).   
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Figure 4.3: Structures of the DNA-binding domains of TALEs PthXo1 and dTale2  
(A) Crystal structure of PthXoI bound to DNA. This structure shows TALE fingers -1 
(purple) and 0 (cyan), and 22 RVD containing repeat fingers coloured in rainbow. In this 
structure, the ½ repeat C-terminal of the repeats is disordered.  
(B) Crystal structure of dTale2 (no DNA). This structure shows TALE fingers -1 (purple) 
and 0 (cyan) as in the PthXo1 structure, and additionaly has two fingers at the N-
terminus which were previously disordered in crystal structures, termed finger -3 and -2 
(pink and magenta respectively). This TALE has 9 RVD containing repeat fingers 
coloured in rainbow. In this structure, the ½ repeat C-terminal of the repeats is shown to 
form a structure similar to the other repeats.  
(Figures made using the crystal structures 3UGM (PthXo1) and 4HPZ (dTALE2). 
A                                                                  B 
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4.2 Designing new TALERs 
 
The design of TALER proteins differs from the design of the TALENs in that 
the TALENs have the nuclease domain attached to the C-terminus of TALE 
DNA-binding domain, while it is deemed necessary to attach resolvase to the 
N-terminus of the DNA-binding domain to create a structure analogous to that 
of the ZFRs which have been seen to be functional (section 1.6.iv). Indeed, 
the ZFRs were utilised as a basis for the break-points used for resolvase in 
the design of the TALER constructs to be discussed in this chapter. 
 
The ‘activated’ Tn3 resolvase NM was selected as the catalytic domain donor 
for the creation of TALER constructs. Tn3-NM resolvase has been previously 
used by our group for creation of active ZFRs (Prorocic et al. 2011; Proudfoot 
et al. 2011), and as such, was deemed to be a good catalytic domain donor 
for the creation of TALERs. Additionally, some useful plasmid constructs were 
available for construction of TALERs. 
 
TALERs are intended to bind to and catalyse a recombination reaction on a 
site consisting of TALE recognition sites flanking the central sequence of the 
Tn3 res site I. Four variants of these sites, termed ‘T-sites’ were constructed, 
with different lengths of spacer between the central sequence from the Tn3 
res site I and the flanking TALE binding sites. These sites, named T-20, T-22, 
T-26 and T-28 after the number of bases separating the DNA-binding 
domains, are shown in figure 4.5. 
Figure 4.4: RVD-DNA Recognition by TALE  
The RVDs which are present in the hey2 TALE binding domain utilised in this study 
(coloured boxes) and the base which they recognise (white boxes) are shown. The 
required conserved 5’ ‘T’ base is also shown.  
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Figure 4.5: The T-Sites used as substrates in this study  
(A) Cartoon depicting position of TALE binding to the sites (as in figure 
4.4). The TALE DNA-binding sites, the central Tn3 res sequence, and the 
intervening spacer sequence are highlighted in red, green and black 
respectively. (B) Sites were designed with different length spacers (black) 
between the central 16 bp res site of Tn3 res site I (green) and the DNA-
binding sites of TALE (red). Sites are named according to the number of 
base pairs between the DNA binding sites; T-20, T-22, T-24 and T-26. 
 
A
 
 
B 
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Having selected the catalytic domain, it was next necessary to choose a 
breakpoint for the resolvase- that is, the position at which to detach the HTH 
DBD of resolvase and attach the TALE construct. The available crystal 
structure data from the closely related  resolvase (Yang and Steitz 1995, Li 
et al 2005), and the position utilised in the zinc finger resolvase work 
previously carried out in the Stark group (Prorocic et al 2011) provided a 
logical position for this attachment; retaining resolvase sequence up to 
residue 148. A model of a potential TALER construct is shown in figure 4.6. 
    
The next step in creating a functional chimeric protein was to select the 
appropriate linker length for attachment of the Tn3 catalytic domain to the 
DNA-binding domain of the TALE and to determine how much of the TAL N-
terminus is required for optimal activity.   
 
Previous studies involving TALEs have indicated that the truncation of the 
TALE domain’s N-terminus can sometimes improve the protein’s activity 
(Miller et al 2010, Zhang et al 2011, Mercer et al 2013). Therefore, in order to 
determine what length of TALE domain is optimal for TALER constructs, 
several N-terminal truncations (48, 84, 119 and 149) were created, and 
the different length TALERs were tested for binding and synapsis in vitro 
(figures 4.7 and 4.8). The 149 variant begins at the start of the ‘-3’ TALE 
finger. The longer truncated variants were created by addition of between 30 
and 35 amino acids, to create TALE ‘finger’ length additions, hypothesising 
the presence of further ‘finger’ like structures N-terminal of the known 
structure.   
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4.3 Construction of TALERs 
 
The TALER constructs utilised in this study employ a previously used TALE 
DNA binding domain from a TALEN construct targeting the zebra fish hey2 
gene (TALEN1297, Sander et al 2011). This construct has a 222 structure, 
with the N-terminal 222 amino acids of the TALE binding domain replaced by 
a 3xFLAG tag and linker sequence and a C-terminal Fok1 nuclease domain 
attachment. In order to utilise this domain for TALER construction, the N-
terminal TALE sequence had to be inserted and the C-terminal nuclease 
domain removed. Due to the repeat nature of the TALE DNA-binding 
domains, TALE domains are difficult to synthesise, thus, two synthetic 
constructs were designed for construction of the desired TALER (figures 4.9 
and 4.10). These constructs were synthesised by GeneArt. 
 
The first of these constructs (GeneArt_SpeI-ApaLI) was designed to link the 
Tn3-NM catalytic domain to the N-terminus of the TALE domain, utilising the 
SpeI restriction site which is at the previously designed attachment point for 
chimeric resolvases (Akopian et al 2003). This construct was also designed 
with silent restriction sites at appropriate intervals to facilitate creation of the 
truncated TALER variants described in the previous section. The second of 
the GeneArt constructs (GeneArt_MfeI-KpnI) was designed to introduce a 
His6 tag for protein purification and termination codons at the C-terminus of 
the protein. These synthetic constructs were cloned into a high copy number 
T7 inducible expression vector with the TALEN-1297 repeat sequence in 
order to create the full-length TALER construct (figure 4.11). The nucleotide 
sequences ordered from MWG are shown (supplementary figures). 
 
These expression vectors were then transformed into BL21(DE3)[pLysS] cells 
and protein production was initiated by IPTG induction as described in section 
2.22. Following induction, samples were loaded onto an SDS polyacrylamide 
gel to determine whether the proteins had been expressed (figure 4.12). 
Following successful expression, the proteins were purified using the C-
terminal His6 tag and dialysed for concentration and further purification 
(section 2.22).  
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Figure 4.11: Construction of TALER expression vectors 
Construction process for creation of expression vector containing full-length TALE (1-(+63)). (A) 
Oligonucleotide SEH13 is cloned in between SpeI and Asp718 of a ZFR containing vector to remove 
the zinc finger DBD and insert the restriction sites NheI and BglII. (B) TALER repeats from 
TALEN1297 (Sander et al 2011) are cloned into the Tn3 vector, using the compatibility of 
BamHI/BglII. (C) Oligonucleotide SEH14 was cloned in between SpeI and MfeI to remove a 3xFLAG 
tag which was present in the TALEN construct. (D) The TALER construct (the TAL domain starting at 
residue 222; TALE finger -1) was excised and inserted into a high copy number, IPTG inducible 
plasmid on an NdeI-Asp718 fragment. (E) Expression vector containing full-length TALE (1-(+63)) 
was constructed by fragment swap between GeneArt synthetic constructs and the 222 TALER 
plasmid pSE2033 (position of RVD containing repeats indicated by brown arrows). 
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4.4: TALER Activity in vivo and in vitro: 
 
TALER constructs were tested in vivo for recombination ability using a 
MacConkey assay with a two site substrate as described in section 2.21. 
However, these assays did not show any evidence of recombination by these 
proteins. All colonies produced were red in colour and making DNA from 
these colonies showed no evidence of recombination activity. This does not 
necessarily indicate that there was no activity, and may instead mean that 
there was a very low level of activity. In vitro recombination assays also 
showed no evidence of activity. As such, more sensitive in vitro cleavage 
assays were carried out. 
 
In vitro cleavage assays utilising a high copy number 2-site substrate (figure 
4.13) were carried out to test each of the four purified truncated TALER 
constructs, 48, 84, 119 and 149 for ability to cleave the T-sites; T-20, T-
22, T-24 and T-26, to test which substrate spacing is optimal for activity of 
these proteins.  The cleavage assay is a sensitive assay which looks at the 
cleavage state of the DNA directly. Cleavage at one site by the TALER would 
be expected to yield a single linear product, while cleavage at both of the 
sites should yield two linear substrates of different sizes.  
 
The shortest of the T-site substrates tested (T-20) was not observed to be 
cleaved by any of the truncated TALERs tested (figure 4.14) indicating that 
this substrate does not have the correct spacing to be functional. The T-22 
substrate when tested was shown to be a functional substrate for cleavage by 
the 149 TALER, though not the other three truncated variants (figure 4.15). 
The T-24 substrate behaved similarly to the T-22, being cleaved by the 149, 
but not by the other variants (figure 4.16). The longest of the substrates 
tested in these assays, T-26 was also a functional site for 149, although it 
does not appear to be as efficient as T-22 and T-24 (figure 4.17).  Increased 
multimer formation seen with 149 constructs indicates cleavage activity and 
increased recombination within these substrates. Multimer formation  
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Figure 4.14: In vitro cleavage assay (T-20 site I)  
Assay for cleavage of T-20 site by the 48, 84, 119 and 149 TALERs. This 
substrate was not acted on by any of the TALER variants with which it was tested, 
leaving the substrate (S) un-cleaved. Expected positions of cleaved substrate (CS) 
are shown. The larger cleaved product ran at a position similar to the un-cleaved 
supercoiled plasmid.  
    T-20 Site I 
   nicked circle 
   S 
   CS 
   CS 
   linear 
multimers 
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Figure 4.15: In vitro cleavage assay (T-22 site I)  
Assay for cleavage of T-22 site by the 48, 84, 119 and 149 TALERs. This 
substrate was cleaved by the shortest of the truncated TALERs (149) cleaving the 
substrate (S) to produce smaller, cleaved products (CS). Cleavage was not seen 
with the longer TALERs. The larger cleaved product runs at a similar position to the 
un-cleaved supercoiled plasmid. 
    T-22 Site I 
nicked circle 
S 
CS 
CS 
linear 
multimers 
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Figure 4.16: In vitro cleavage assay (T-24 site I)  
Assay for cleavage of T-24 site by the 48, 84, 119 and 149 TALERs. This 
substrate was cleaved by the shortest of the truncated TALERs (149) cleaving the 
substrate (S) to produce smaller, cleaved products (CS). Cleavage was not seen 
with 48, 84 and 119 TALERs. The larger cleaved product runs at a position 
similar to the un-cleaved supercoiled plasmid. 
    T-24 Site I 
nicked circle 
S 
CS 
CS 
linear 
multimers 
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     T-26 Site I 
Figure 4.17: In vitro cleavage assay (T-26 site I):  
Assay for cleavage of T-26 site by the 48, 84, 119 and 149 TALERs. Cleavage 
was carried out only by the shortest of the truncated TALERs (149) acting on the 
substrate (S) to create smaller, cleaved products (CS). Cleavage was not seen with 
the longer TALER variants. 
nicked circle 
S 
CS 
CS 
linear 
multimers 
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increases in the T-24 and T-26 substrates, indicating that these are being 
acted on more efficiently by the 149 TALER. 
 
These assays indicated that the best of the substrates tested were the T-22 
and T-24 substrates which show similar amounts of cleavage products, and 
additionally showed that the longer truncated variants, 48, 84 and 119 are 
not functional under these conditions, while the shortest of the TALER 
constructs, the 149 construct, was functional on three of the four substrates.     
Following these in vitro cleavage assays therefore, the T-22 site was selected 
for further study.  
 
Of the TALERs tested, only the protein with the largest TALE domain N-
terminal truncation was shown to have activity on the T-site substrates. This 
could be because the other proteins are unable to bind to their sites, because 
the additional amino acids at the N-terminus of the longer constructs are 
folding in such a way that they are blocking protein-protein interactions and 
thus preventing the formation of the dimer and tetramer constructs which are 
necessary for activity of the resolvase catalytic domain, or because the 
additional length at the N-terminus is blocking access of the resolvase to the 
centre of the res site.   
 
In order to test whether the TALER constructs are able to bind to the DNA 
and to determine what types of protein interactions are formed, 75 bp T-22 
linear DNA ordered from MWG as oligonucleotides (SEH 48-T and SEH 48-B) 
was labelled with 32P-ATP and in vitro binding assays were carried out.  The 
assays showed that the 48, 84, 119 and 149 truncated TALER variants 
are all able to bind to the site, indicating that the binding domains are 
targeting their designed sites (figure 4.18).  
 
The results of the in vitro band-shift assay shown in figure 4.18 agree with the 
results obtained from the in vitro cleavage assays in that they show that the 
149 TALER forms three complexes on the gel, where the 48, 84 and 
119 constructs form only two complexes on the gel. These complexes, if the  
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Figure 4.18: In vitro binding band-shift assay  
T-22 32P-ATP labelled sites bound by 48, 84, 119 and 149 TALERs. The 149 
construct is able to form a large complex (3) (hypothesised to be a synaptic tetramer 
complex) the 84 and 149 constructs form putative dimer structures (2) and the 48 and  
119 structures appear to form only a hypothesised monomeric structure (1).      
3   Tetramer 
 
2   Dimer 
 
1   Monomer 
 
 
 
 
U   Unbound 
BL         48           84               119         149   
-
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TALER is behaving as hypothesised, in a manner similar to the resolvases, 
may be representative of complexes containing one, two and four TALER 
subunits, similar to the complexes which were demonstrated in chapter 3 for  
the full-length and truncated Sin constructs. It is hypothesised that the largest 
of these complexes could be a synapse containing 4 protein subunits and two 
DNA sites. Confirming this hypothesis however requires more research to be 
carried out, such as the mixed-length (45 bp and 77 bp) DNA substrates used 
to identify the ‘tadpole’ synapse in chapter 3. 
 
 
4.5: Discussion 
 
In this chapter, TALERs with various extents of N-terminal truncation of the 
TALE DNA-binding domain were tested for their ability to carry out binding, 
recombination and cleavage in vivo and in vitro. These TALERs were tested 
on substrates with different length spacers between the central 16 bp of the 
resolvase res site and the 17 bp DNA binding sites of the chosen TALE (T-20, 
T-22, T-24 and T-26).  It was determined that the largest truncation of the N-
terminal domain (149) was the most efficient of the TALERs tested, as only 
the 149 protein was able to carry out cleavage in vitro and form what is 
hypothesised to be a synaptic tetramer-like structure in band-shift assays.  
 
The failure of the longer TALER variants (48, 84 and 119) to form the 
larger protein complex and their inability to carry out cleavage assays may be 
due to the extra length at the N-terminal end of the TALE domain folding in a 
way that is detrimental to the ability of the protein to form the necessary 
protein-protein interactions for synapsis of the NM catalytic domains.  
 
As there are no crystal structures available for TALE sequence N-terminal of 
the ‘-3’ repeat, this region may be disordered, a state which may not be as 
detrimental to TALEN constructs, as the attachment site for the nuclease 
domain in such constructs is typically at the C-terminus of the TALE protein 
rather than the N-terminal attachment site utilised for these TALERs.  
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This C-terminal region is quite proline rich, and prolines are disruptors of 
secondary structures such as the -helices which form the repeat fingers in 
the TALE binding domains.  
 
It is also possible that the inability of the TALER to be catalytically active may 
be due to there being an excess of amino acids between the DNA-binding 
domain and the catalytic domain, blocking the catalytic domain of NM 
resolvase from having access to the centre of the site in order to carry out 
catalysis. The 149 TALER, with less protein between the catalytic domain 
and the DNA-binding domain is functional, and this may be because this 
construct places the catalytic domain in a position which permits access to 
the centre of the site for cleavage to take place.   
 
It was also determined that of the T-site spacers tested, the shortest, (T-20) is 
not a viable site for the TALERs; the optimal spacing for the TALERs of the 
spacers tested were the T-22 and T-24 constructs, while the T-26 construct is 
less efficiently cleaved. The 22 base pair and 24 base pair spacing between 
the TALER binding sites was therefore shown to provide the correct distance 
to be accessible to the catalytic domain of the 149 TALER. Interestingly, the 
optimal spacing observed for the TALERs is the same as the optimal spacing 
previously utilised for the ZFRs (Akopian et al 2003, Proudfoot et al 2011). 
 
The three complexes seen for the 149 construct are hypothesised to be 
monomer, dimer and tetramer complexes- a hypothesis which is supported by 
the evidence that the 149 protein, the only protein seen to form this 
hypothesised tetramer complex, is also the only protein able to carry out 
cleavage. However, the presence of distinct monomer, dimer and tetramer 
complexes is not conclusively shown in this study. In order to confirm this 
hypothesis, assays similar to those carried out in chapter 3, utilising different 
lengths of labelled T-site, should be carried out to determine whether the 
putative tetramer complex does indeed contain two molecules of DNA.  
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Further work to characterise these TALER constructs would include the 
creation of more truncated variants, to determine whether further truncations 
could increase the activity of the protein beyond that seen in TALER 149, 
the shortest construct tested in this work and the addition of various flexible 
linker domains between the catalytic domain and the DNA binding domain in 
an attempt to optimise the positioning of the DNA binding domains relative to 
the catalytic domains when bound to the DNA. Additionally, the creation of T-
sites with further different lengths of spacer between the DNA binding region 
and the centre of the site may provide a more optimal substrate for activity of 
TALERs, providing better spacing for the TALER to access the site and carry 
out recombination.  
 
During the course of this study, another group reported TALER-mediated 
recombination activity, using gin invertase as a catalytic domain and the 
TALE DNA-binding domain AvrXa7 (Mercer et al 2012). The Gin-TALER work 
was carried out in vivo. They made both 3’ and 5’ attachments of the TALE 
AvrXa7 to Gin, demonstrating that, as hypothesised for the creation of my 
own TALER, only the attachment of TALE to the C-terminus of Gin was 
functional. They also carried out various N-terminal truncations, finding, as I 
did, that N-terminal truncation of the TALE DNA-binding domain produced 
more active variants. The recombination activity which they observed was not 
as good as that which their lab had previously observed with gin-ZFRs (Gaj et 
al 2010), with only approximately 7% recombination observed in vivo, even 
with the most active Gin-TALER variant.   
 
So far TALERs have not proved to have the robust recombination activity 
observed with the ZFR proteins. The failure of the TALER constructs to 
recombine suggests that the positioning of the catalytic domain and DNA 
binding domains relative to the T-site is not yet optimal, preventing the 
necessary recombination complex from forming in a stable manner and thus 
preventing recombination. Hopefully further work will better characterise these 
proteins, leading to more efficient variants with activities analogous to the 
activity which has been observed to date with the ZFRs.  
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Chapter 5: Conclusions and discussion 
 
 
This work had two main goals; firstly, to examine the importance of the E-
helix of Sin for synapsis at site I, and to determine the important residues in 
this interface, and secondly, to create a chimeric TALER construct, with the 
ability to be targeted to a site determined by the TALE DNA-binding domain. 
 
Chapter 3 discussed the sequence selectivity of Sin resolvase-mediated 
binding and synapsis of site I. It was shown that altering the nucleotides at the 
centre of site I from the Sin nucleotides to the corresponding Tn3 nucleotides 
negatively effects binding by Sin; highlighting the importance of recognition of 
these bases by the protein. It was also demonstrated that both halves of the 
site are required for the formation of dimer and synaptic tetramer complexes 
of resolvase. 
 
Assays with the truncated ‘tadpole’ variants show that those with the E-helix 
intact are competent for binding and synapsis, but deletion of the residues 
between 109 and 124 of the E-helix blocks the formation of a synapse, 
highlighting the importance of this region of the protein for formation of a 
tetramer of E-helices. 
 
Swapping the ‘arm’ region of Sin with the equivalent residues from Tn3 
resolvase prevented the formation of a synaptic complex on the Sin site I, 
again demonstrating that residues within the E-helix ‘arm’ region do have 
specificity for binding at the site. The ability of the longest ‘tadpole’ (101) to 
form a synapse at the site was unexpected, and may be due to co-operative 
binding and the E-helix interactions of the protein conferring stability to the 
protein. Blocking of the formation of the synapse, both by alteration of the 
‘arm’ region of the E-helix and by alteration of the DNA sequence at the 
centre of the site, demonstrates that the sequence at the centre of the res site 
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is important, and that the ‘arm’ region of resolvase is making specific contacts 
with these nucleotides.  
 
Mutations made within the E-helix, (between residues 110 and 121) both on 
the flat, hydrophobic interface between the E-helices and on the outside of 
the interface (as discussed in section 3.6) demonstrated that, as predicted 
from the crystal structure data, residues on this interface are important to 
synapsis. From the crystal structures, it can be additionally seen that these E-
helix residues have potential interactions between the E-helices and the 
catalytic domains, either in cis (I114 and S121) or in trans (L112, I116 and 
M119) and between the anti-parallel E-helices (L112, I116 and M119), 
forming interactions which hold the ‘rotational dimers’ together. These 
mutations also highlighted the similarity in behaviour between these ‘tadpole’ 
constructs and their full-length activated counterparts, lending credence to the 
hypothesis that the E-helix bundle at the centre of the tetramer, discussed in 
chapter 3, acts as a basic synapsis-competent module.  
 
Chapter 4 concerned the creation of chimeric TALER proteins, and 
demonstrated that it is possible to create a TALER with the ability to bind to 
its target site and which is able to carry out cleavage in vitro. However, the 
Tn3-TALER created in this study was not observed to have recombination 
activity. Further optimization of the linker length and site spacing may yield 
more efficient TALER variants with activities analogous to those which have 
been observed to date with the ZFRs.  
 
The TALER constructs discussed in this work used a single TALE DNA-
binding domain, targeted to identical sites flanking the Tn3 resolvase res site. 
In order for TALER constructs to be targeted to a desired region within 
genomic sequence, creation of heterodimeric TALERs, which are able to 
target different DNA-sites would be desirable. Such heterodimeric constructs 
would be useful for targeting biologically relevant sites within the genome.  
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The work discussed in chapter 3 has highlighted the sequence selectivity of 
the resolvase ‘arm’ region, and it is also known that the catalytic domain of 
resolvase has sequence selectivity for the centre of the site. A further goal for 
the creation of chimeric recombinases such as TALERs for use as tools in 
biotechnology or genetic surgery would be the creation of chimeric proteins 
with the selectivity of the recombinase domain removed, creating a non-
selective recombinase, which is fully reliant on the sequence specificity 
inherent to the DNA-binding domain of the TALE. Such a protein would 
provide an alternative to the TALENs which have been widely discussed in 
the literature. This approach however would require a vast amount of complex 
protein engineering, may prove very difficult, and is a goal for the future. 
Future work to further examine the important residues in the catalytic module 
and the E-helix of resolvase may shed more light on ways to make more 
efficient chimeric TALE recombinases with potential applications in 
biotechnology and genetic engineering.   
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SpeI                                                                                                                                                  PfoI 
|     1                                                                                                                                            48 |      
ACTAGTGATCCCATTCGTTCGCGCACGCCAAGTCCTGCCCGCGAGCTTCTGCCCGGACCCCAACCGGATAGTGTACAGCCGACTGCAGATCGGGGGGGGGCTCCGCCTGCTGGCGGCCCCCTGGATGGCTTGCCCGCTCGGCGGACGATGTCCCGG  
T  S  D  P  I  R  S  R  T  P  S  P  A  R  E  L  L  P  G  P  Q  P  D  S  V  Q  P  T  A  D  R  G  G  A  P  P  A  G  G  P  L  D  G  L  P  A  R  R  T  M  S  R   
 
                                                                                                                   SacII 
                                                            84                                                     |                                         
ACCCGGCTGCCATCTCCCCCTGCGCCCTCGCCTGCGTTCTCGGCGGGCAGCTTCAGCGATCTGCTCCGTCAGTTCGATCCGTCGCTTCTTGATACATCGCTTCTTGATTCGATGCCCGCGGTCGGCACGCCGCATACAGCGGCTGCCCCAGCAGAG  
T  R  L  P  S  P  P  A  P  S  P  A  F  S  A  G  S  F  S  D  L  L  R  Q  F  D  P  S  L  L  D  T  S  L  L  D  S  M  P  A  V  G  T  P  H  T  A  A  A  P  A  E   
 
                                                  BsiWI                                                                                            SalI 
                                                119                                                                                    149         |         
TGCGATGAGGTGCAATCGGGTCTGCGTGCAGCCGATGACCCGCCACCCACCGTACGTGTCGCTGTCACTGCGGCGCGACCGCCGCGCGCCAAGCCGGCCCCGCGACGGCGTGCGGCGCAACCCTCCGACGCTTCGCCGGCAGCGCAGGTCGACTTG  
C  D  E  V  Q  S  G  L  R  A  A  D  D  P  P  P  T  V  R  V  A  V  T  A  A  R  P  P  R  A  K  P  A  P  R  R  R  A  A  Q  P  S  D  A  S  P  A  A  Q  V  D  L   
 
 
AGGACCCTAGGTTATTCGCAACAGCAACAGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTCACTCATGCGCATATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCT  
R  T  L  G  Y  S  Q  Q  Q  Q  E  K  I  K  P  K  V  R  S  T  V  A  Q  H  H  E  A  L  V  G  H  G  F  T  H  A  H  I  V  A  L  S  Q  H  P  A  A  L  G  T  V  A   
 
 
GTCAAATACCAAGATATGATTGCGGCCCTGCCCGAAGCCACGCACGAGGCGATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGACTGTGGCGGGTGAGCTTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAG  
V  K  Y  Q  D  M  I  A  A  L  P  E  A  T  H  E  A  I  V  G  V  G  K  Q  W  S  G  A  R  A  L  E  A  L  L  T  V  A  G  E  L  R  G  P  P  L  Q  L  D  T  G  Q   
 
                                             ApaLI 
                                             |      
CTGCTGAAGATCGCGAAGAGAGGGGGAGTAACAGCGGTAGAGGCAGTGCAC  
L  L  K  I  A  K  R  G  G  V  T  A  V  E  A  V  H 
 
 
Supplementary 1: GeneArt construct TAL_SpeI-ApaLI 
The full nucleotide sequence of the synthetic construct TAL_SpeI-ApaLI ordered from MWG for construction of the 
TALER expression plasmid. The location of the introduced silent restriction sites and the truncation points which they 
introduce is shown.  
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MfeI 
|                                                                                                                                                            
CAATTGTCCAGGCCCGATCCCGCGTTGGCTGCGTTAACGAATGACCATCTGGTGGCGTTGGCATGTCTTGGTGGACGACCCGCGCTCGATGCAGTCAAAAAGGGTCTGCCTCATGCTCCCGCATTGATCAAAAGAACCAACCGGCGAATTCCCGAG  
Q  L  S  R  P  D  P  A  L  A  A  L  T  N  D  H  L  V  A  L  A  C  L  G  G  R  P  A  L  D  A  V  K  K  G  L  P  H  A  P  A  L  I  K  R  T  N  R  R  I  P  E   
 
                                                KpnI 
                                                |      
AGAACTTCCCACCGAGTGGCGCATCACCATCACCATCACTGATGATCAGGTACC  
R  T  S  H  R  V  A  H  H  H  H  H  H  *  *  S  G  T 
 
Supplementary 2: GeneArt construct TAL_MfeI-KpnI 
The full nucleotide sequence of the synthetic construct TAL_MfeI-KpnI ordered from MWG for construction of the 
TALER expression plasmid. The location of the introduced histidine tag and termination codons is shown.  
